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1 Introduction 
 Obesity and adipose tissue  
Obesity is defined as an imbalance between energy uptake and energy 
consumption which leads to an abnormal increase in body fat (Klish, 1995). 
According to the world health organization (WHO) more than 1.9 billion 
adults were overweight and more than 600 millions of these were obese in 
2014 (WHO, 2016). Overweight and obesity can be classified by the body 
mass index (BMI). Adults with a BMI between 26-29.99 are overweight 
whereas adults with a BMI larger than 30 are obese (WHO, 2016). Obesity 
can be accompanied by several comorbidities like hypertension, diabetes 
mellitus type II, gout, gallbladder disease, and cardiovascular diseases. 
These diseases are a growing worldwide problem as the number of obese 
people doubled since 1980 (WHO, 2016). Obesity places an enormous 
burden for the society and health care systems as well as on the afflicted 
individuals themselves (Khaodhiar et al., 1999; Lobstein et al., 2015) 
(WHO, 2017). Consequently, the funding for research aiming to identify 
potential targets, aiding to treat obesity-associated diseases has been 
substantially increased. Recent studies have revealed that targeting the 
adipose tissue could be a solution (Harms and Seale, 2013).  
The adipose tissue is an important organ as it is responsible for the storage 
of lipids as major energy source and thereby it controls the energy 
homeostasis (Galic et al., 2010). Importantly, different types of adipose 
tissue exist in mammals with discrete functions. Mammalian adipose tissue 
is classically categorized into two different types, the white and the brown 
adipose tissue. Each of these is characterized by a specific population of 
adipocytes and is found at distinct regions. Furthermore, beige adipose 
tissue can occure within the classical white adipose tissue (Figure 1). 
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Figure 1: Location of brown, white and beige adipocytes in mice and humans (modified from 
(Bartelt and Heeren, 2014)). 
In mice, brown adipocytes are located in the interscapular region. The inguinal adipose tissue contains a 
mixture of beige and brown adipocytes and the gonadal adipose tissue only contains white adipocytes. In 
humans, brown adipocytes can be found deep in the neck, close to muscle tissue. The subcutaneous 
adipose tissue only contains white adipocytes. Moreover, supraclavicular is characterized by the 
expression of white, beige and brown adipocytes. 
 
  White adipose tissue (WAT) 
The white adipose tissue (WAT) is found predominantly around the gonads 
(WATg, gonadal white adipose tissue) and subcutaneously close to the hind 
limbs (WATi, inguinal white adipose tissue) in mice. In humans, the major 
sites of WAT are located under the skin (subcutaneous WAT) or associated 
with the digestive tract (visceral WAT) (Bartelt and Heeren, 2014; Cinti, 
2005). Morphologically, white adipocytes (WAs) contain one large lipid 
droplet which is located in the cytoplasm of the cell (also called unilocular) 
(Cinti, 2005) (Figure 2).   
brown adipocytes
beige adipocytes
white adipocytes
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The main function of WAT is energy storage. However, in case of chronic 
excessive energy intake, fatty acids are no longer safely cleared from 
systemic circulation and accumulate in other organs such as the liver and 
the muscle (Frayn et al., 2006). This is known as lipid spillover or ectopic 
lipid deposition (Unger and Scherer, 2010). Apart from an energy 
repository, WAT functions as an endocrine organ, secreting hormones (like 
leptin and adiponectin) chemokines and cytokines and thereby influencing 
the metabolic homeostasis, inflammatory processes and vascular 
homeostasis (Galic et al., 2010; Ouchi et al., 2011; Trayhurn and Beattie, 
2001). Thus far, no specific markers for WAT have been identified. 
However, several genes including fatty acid binding protein (aP2), 
peroxisome proliferator-activated receptor g (PPARg) and CCAAT/enhancer-
binding protein a (C/EBPa) are highly expressed in WAT and have an 
important role in WAT differentiation (Shao and Lazar, 1997). The 
transcription factor C/EBPa is crucial for the regulation of energy 
metabolism, whereas PPARg influences glucose metabolism and insulin 
sensitivity (Choi et al., 2010).  
 
 
Figure 2: Different types of adipocytes (modified from (Pfeifer and Hoffmann, 2015)). 
For decades, the different types of adipocytes were divided into two groups: the white adipocytes, which 
contain one single large lipid droplet and the brown adipocytes containing multilocular lipid droplets and 
high abundancy of mitochondria. Recently, an intermediate type was discovered: the beige adipocytes. 
Those are characterized by multilocular lipid droplets and a high number of mitochondria, however they 
are located in classical WAT. 
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  Brown adipose tissue (BAT)   
The second type of adipose tissue is the brown adipose tissue (BAT) which 
consumes energy for non-shivering thermogenesis instead of storing 
energy. Previously, it was widely accepted that BAT is only present in 
newborns and atrophies during growth. In 2009, innovative studies by using 
positron-emission-tomography/computed tomography (PET/CT) showed 
that human adults have active BAT (Virtanen et al., 2009). In humans, BAT 
is located in the neck region, supraclavicular and perirenal (van Marken 
Lichtenbelt et al., 2009; Virtanen et al., 2009). In rodents, BAT is located in 
the interscapular region, between the shoulder blades, and to a lesser 
extent as perirenal and axillary BAT (Figure 1) (Lidell et al., 2013). Brown 
adipocytes (BAs) and WAs both have the capacity to store lipids, although 
they are derived from different precursor cells (Seale et al., 2008). The 
precursor cells of BAs are derived from the same lineage as skeletal muscle 
cells. BA progenitors express bone morphogenic protein 7 (BMP7) and 
PRD1-BF-1-RIZ1 homologous domain containing protein-16 (PRDM16) 
during development and this drives them into mature BAs (Seale et al., 
2008; Tseng et al., 2008). In contrast to WAs, BAs contain multiple smaller 
lipid droplets (multilocular), and they are rich in mitochondria (Cinti, 2005) 
(Figure 2).  
Thermogenesis by BAT is controlled by the sympathetic nervous system. 
Upon stimulation by stimuli such as cold exposure, sympathetic nerves in 
BAT release Norepinephrine (NE). NE then binds to and activates b3-
adrenergic receptors (b3-AR) on the surface of the BAs. This leads to 
increased intracellular 3’, 5’ cyclic adenosine monophosphate (cAMP) levels, 
which activates protein kinase A (PKA) (Matthias et al., 2000). PKA 
activates the hormone-sensitive lipase (HSL), which catalyzes the hydrolysis 
of free fatty acids (FFA) (Shih and Taberner, 1995). The FFA mediate the 
activation of uncoupling protein 1 (UCP1) (Cannon and Nedergaard, 2004; 
Sell et al., 2004). UCP1 is a polypeptide that serves as a proton transporter 
in the inner mitochondrial membrane and disrupts the electrochemical 
proton gradient (Cannon and Nedergaard, 2004; Cinti, 2005). By this, UCP1 
allows the uncoupling of respiration from ATP synthesis. This uncoupling in 
turn drives high levels of substrate oxidation (especially glucose and fat) 
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and results in generation of heat (Cannon and Nedergaard, 2004; Kozak 
and Harper, 2000; Yamada et al., 1992). Additionally, stimulation of PKA 
activates the P38 mitogen-activated protein kinase that activates and 
phosphorylates PGC-1a through activating transcription factor 2 (ATF2) 
(Cao et al., 2004). PGC-1a directly interacts with nuclear respiratory factor 
(NRF), like NRF1 and NRF2, to stimulate de novo mitochondrial biogenesis 
and additionally with different protein complexes to induce the transcription 
of UCP1 (Robidoux et al., 2006; Rosen et al., 2000; Thonberg et al., 2002).  
It has been suggested that in humans BAT activity can contribute 5 % of 
the basal metabolic rate, mediated by UCP1 expression. This indicates a 
regulatory role of BAT in energy balance and hence body weight (van 
Marken Lichtenbelt and Schrauwen, 2011). In adult humans, UCP1 
expression in BAT is negatively correlated with obesity and its expression 
diminishes with age (Saito et al., 2009; van Marken Lichtenbelt et al., 
2009). Studies on severely obese patients demonstrate that weight loss 
induced by bariatric surgery increases BAT activity (Vijgen et al., 2012; 
Vijgen et al., 2011). Furthermore, investigations on healthy Japanese men 
revealed that single nucleotide polymorphisms in human UCP1 and ADRB3 
(Gene of b3-AR) result in increased age-related decline of BAT activity and 
visceral fat accumulation (Nakayama et al., 2013; Yoneshiro et al., 2011; 
Yoneshiro et al., 2013). Nevertheless, studies to increase BAT mass and 
activity in humans after repetitive cold exposure showed increased glucose 
clearance and insulin sensitivity (Blondin et al., 2014; Lee et al., 2014b). 
These results unravel the adipose tissue as a valuable therapeutic target to 
treat metabolic diseases and obesity in humans. 
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  Beige adipose tissue 
Recently, an intermediate type of adipocytes has been identified: the beige 
or brite (brown in white) adipocytes (Wu et al., 2012). Beige adipocytes 
share several characteristics of BAs like multilocular lipid droplets, a high 
number of mitochondria and expression of UCP1, but they are located in 
classical WAT (Bordicchia et al., 2012; Gnad et al., 2014; Mitschke et al., 
2013; Rosen and Spiegelman, 2014; Seale et al., 2011) (Figure 1). The 
origin of beige fat cells is not well understood and different hypotheses 
exist: one idea is that beige fat cells can arise directly from Myh11+ smooth 
muscle precursor cells (Long et al., 2014). Long et al. crossed transgenic 
mice expressing Myh11-driven Cre with GFP reporter mice. Cold exposure 
increased the number of beige adipocytes in WATi but not in BAs. They also 
demonstrated in fate mapping experiments and UCP1-TRAP data that 
mature Myh11-expressing cells suppress their smooth muscle gene 
signature during differentiation into mature beige adipocytes. Classical 
brown adipocytes have been described to derive from the same 
Pax7+/Myf5+ lineage as skeletal muscle cells, whereas white und beige 
adipocytes derive from Pax7+/Myf5- cells (Seale et al., 2008). Other notions 
are that beige cells derive from preadipocytes or mesodermal stem cells or 
through transdifferentiation from white to beige adipocytes (so called 
browning) (Asano et al., 2014; Kajimura and Saito, 2013; Sanchez-
Gurmaches et al., 2015; Sanchez-Gurmaches et al., 2012). Several 
situations might be true in different adipose depots, as the abundance of 
beige cells varies dramatically between them. Beige adipocytes content in 
WATg is not as high as of WATi. WATi is responsive to browning even with 
mild NE stimulation, whereas WATg of male mice is largely resistant to 
beige adipocyte recruitment (Kim et al., 2016; Okamatsu-Ogura et al., 
2013; Shabalina et al., 2013). In addition, studies on human white adipose 
tissue reveal also browning capacity (Jespersen et al., 2013; Wu et al., 
2012).  
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 NO/sGC/cGMP pathway 
The nitric oxide (NO)/ soluble guanylate cyclase (sGC)/ 3’-5’cyclic 
guanosine monophosphate (cGMP) pathway plays an important role in 
different physiological processes, for example relaxation of the smooth 
muscle cells, platelet aggregation and cell differentiation (Ignarro et al., 
1999; Pfeifer et al., 1998). The NO/cGMP pathway is also important for the 
differentiation of BAs, shown in Figure 3. NO is a gaseous molecule 
produced by different nitric oxide synthases (NOS). It binds to sGC and 
thereby activates sGC to produce cGMP from guanosine triphosphate (GTP) 
(Forstermann and Sessa, 2012). Treatment of BAs during differentiation 
with NO and cGMP increases the expression of the transcription factor PGC-
1a and UCP1 (Nisoli et al., 1998). Endothelial NOS (eNOS) knockout mice 
have a higher body weight in comparison to wild type (WT) mice (Nisoli et 
al., 2003). These results reveal that a deficiency in eNOS function leads to a 
reduced energy consumption, favoring weight gain. cGMP functions as a 
second messenger in the cell and affects different phosphodiesterases 
(PDEs), cyclic nucleotide gated cation channels (HCN) as wells as cGMP-
dependent protein kinase (PKG) (Biel et al., 1999; Francis et al., 2010a; 
Francis et al., 2010b; Pfeifer et al., 1999). Employing gain and loss of 
function models Haas et al. demonstrated the importance of the cGMP/PKGI 
pathway for the differentiation of BAs (Haas et al., 2009). The loss of PKGI 
leads to an impairment of adipogenesis in BAs. PKGI knockout mice have 
decreased expression levels of aP2 and PPARg as well as the thermogenic 
marker UCP1 compared to WT mice (Haas et al., 2009). In contrast, 
overexpression of PKGI leads to increased expression of adipogenic markers 
and UCP1 as well as improved mitochondrial biogenesis and protection from 
diet-induced obesity (DIO) (Miyashita et al., 2009). One important 
downstream target of PKGI is RhoA. PKGI phosphorylates RhoA and thereby 
releases the inhibitory effect of RhoA/ROCK on insulin signaling. The insulin 
receptor substrate 1 (IRS1) transmits insulin binding to its receptor into 
mitochondrial biogenesis and adipogenic differentiation(Haas et al., 2009).  
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A major downstream (phosphorylation) target of PKGI is the vasodilator-
stimulated phosphoprotein (VASP). Deletion of VASP results in increased 
cGMP signaling in adipocytes and enhanced browning of WATi, indicative of 
a negative feedback loop regulating cGMP levels in BAs (Jennissen et al., 
2012). The pathway has been explained in more detail in the following 
chapters.  
 
Figure 3: Effect of NO/sGC/cGMP pathway in brown adipocytes.   
Two GC exist that generate cGMP from GTP, one is the sGC stimulated by NO and the other one is pGC 
which is activated by NPs. Increased cGMP leads to activation of the adipogenic (increased PPARg, aP2 
expression and TG content) and thermogenic program (increased expression of UCP1 and PGC-1a) in 
BAs.    
 
 Production of NO 
The gaseous signaling molecule NO is produced endogenously by NOS from 
the amino acid L-arginine that is either also produced endogenously or 
generated from food intake (Mayer and Hemmens, 1997; Murad, 2006). 
Three different subtypes of NOS have been identified so far: neuronal NOS 
(nNOS) which is expressed in neurons, heart, and skeletal muscle cells and 
produces NO after binding to Calmodulin (Weissman et al., 2002). NO 
produced by nNOS is an important neurotransmitter mainly in non-
adrenergic non-cholinergic nerves (Bowman et al., 1986; Gillespie et al., 
1989). eNOS is located in endothelial cells and the activation of eNOS is 
regulated by fluid shear stress (Forstermann and Sessa, 2012). The third 
subtype is inducible NOS (iNOS) which is present in macrophages/ glia cells, 
and its expression can be induced by lipopolysaccharides, glucocorticoids 
and cytokines (Daff, 2010; Murad, 2006; Stuehr et al., 1991). The 
production of NO by the different subtypes of NOS leads to the activation of 
the major enzyme class guanylate cyclase (GC).  
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 Guanylate cyclases 
The GCs are members of the nucleotide cyclase class and catalyze the 
conversion of GTP to cGMP. GCs are classified in sGC and particular GCs 
(pGC) (Lucas et al., 2000; Tesmer and Sprang, 1998). While pGCs are 
active as a monomer, sGC is only catalytically active when present as a 
heterodimer (Lucas et al., 2000; Tesmer and Sprang, 1998).   
1.2.2.1 Particular guanylate cyclase (pGC) 
Natriuretic peptide receptors (NPRs) are activated by atrial natriuretic 
peptide (NP) (ANP), B-type NP (BNP) as well as C-type NP (CNP) (Kuhn, 
2009, Potter et al 2009). NPRA (GC-A) is activated by ANP and BNP, 
whereas NPRB (GC-B) is only activated by CNP. The stimulation of GC-A by 
ANP and BNP for example regulates blood pressure and prevents fibrosis 
(Kuhn, 2003; Potter et al., 2006), whereas activation of GC-B by CNP 
inhibits the proliferation of fibroblasts in the heart, for instance (Bocciardi et 
al., 2007; Obata et al., 2007). The ligands guanylin and uroguanylin bind to 
GC-C and regulate intestinal fluid balance. Other subtypes of pGC are 
expressed in the olfactory neuroepithelium (GC-D), in the retina (GC-E and 
GC-F) (Potter, 2011) or in the intestine, lung and skeletal muscle cells (GC-
G). The subtypes GC-D to GC-G are also known as orphan receptors (Lucas 
et al., 2000). All pGCs exhibit the same structure, an extracellular ligand 
binding domain, a transmembrane domain (TM), a kinase homology domain 
and a high conserved catalytic domain (Potter et al., 2006).  
  
1.Introduction 
                                                  
 
 
10 
1.2.2.2  Soluble guanylate cyclase (sGC) 
sGCs are heterodimeric heme-binding proteins consisting of a and 
b subunits, organized in heterodimer combinations of a1/b1 and a2/b1 (Friebe 
and Koesling, 2009b; Potter, 2011; Russwurm et al., 1998). The function of 
the b2 subunit remains elusive (Derbyshire and Marletta, 2012). The 
heterodimer a1/b1 is ubiquitously expressed, whereas the a2/b1 combination 
of sGC is highly expressed in lung, brain, adipose tissue, spleen, uterus, 
placenta, heart and colon (Bellingham and Evans, 2007; Budworth et al., 
1999; Jennissen et al., 2012; Potter, 2011).  
The structure of sGC is characterized by an N-terminal regulatory domain, a 
C-terminal catalytic domain, a Per/Ant/Sim (PAS) domain and an a-helix. 
For the dimerization of the a and b subunits the PAS domain and the a-helix 
are necessary (Ma et al., 2008). The heme binding site is located in the N-
terminal regulatory domain and is required for stimulation of sGC by NO. 
The catalytic domain of sGC is responsible for the conversion of GTP to 
cGMP and is located in the C-terminal part (Chang et al., 2005; Lucas et al., 
2000).  
Deletion of the β1 subunit ablates sGC enzymatic activity (Friebe et al., 
2007). Genetically modified mice lacking the sGCb1 subunits exhibit a severe 
phenotype with higher blood pressure, reduced heart rate and a 
dysfunctional contraction of the gastrointestinal tract (Friebe et al., 2007). 
Overall, sGCb1 knockout mice have a shorter lifespan in comparison to WT 
mice. These findings underpin the central and crucial role of sGC for the 
entire organism (Friebe and Koesling, 2009a; Friebe et al., 2007).  
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 sGC as a drug target  
sGC has been used as a drug target since 1860 (Murrell, 1879). First, 
organic nitrates such as glyceryl nitrate were used as treatments for angina 
pectoris (Sandler et al., 1963). Nitrates are metabolized to release NO, 
which is relieving the acute symptoms of arterial hypertension and coronary 
artery disease. However, nitrate tolerance rapidly emerges and reduces the 
efficiency of these compounds, potentially in part through a mechanism 
leading to sGC heme oxidation (Jabs et al., 2015; Munzel et al., 1995).  
More recent discovered compounds directly target and increase sGC 
activity. The first NO-independent stimulator was the benzylindazole 
derivate YC-1. Due to its NO-independent sGC-stimulating properties YC-1 
was used as a lead structure for the synthesis of BAY 41-2272 and BAY 41-
8543. These compounds possess a stronger affinity to sGC and thereby 
further enhance the stability of the NO-heme complex compared to YC-1 
(Schmidt et al., 2003; Stasch et al., 2002a; Stasch et al., 2002b).  
Different studies showed that BAY 41-2272 and BAY 41-8543 inhibit platelet 
aggregation, decrease proliferation of vascular smooth muscle cells and lead 
to vasodilation (Nossaman et al., 2012; Stasch et al., 2002b). The clinical 
application of BAY 41-8543 is precluded by adverse drug metabolism and 
pharmacokinetic properties, including high clearance and dose non-linearity 
of plasma concentrations (Mittendorf et al., 2009).  
Further optimization of these compounds resulted in the discovery of a new 
sGC stimulator. In vitro studies revealed that treatment with Riociguat (BAY 
63-2521) activates sGC in a dose dependent manner. In addition, it exhibits 
a higher degree of specificity and no side effects towards inhibition of PDE 
compared to the earlier sGC stimulator (Schermuly et al., 2008). Riociguat 
has a superior profile of drug metabolism and pharmacokinetics compared 
to other drugs of this family. It also has a favored oral bioavailability and 
hemodynamic profile. Recently, Riociguat completed phase III clinical trials 
and is now approved by the FDA and EMA for treatment of pulmonary 
hypertension (Ghofrani et al., 2013a; Ghofrani et al., 2013c; Mittendorf et 
al., 2009).   
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 Effector molecules of the second messenger cGMP  
cGMP is affecting different cGMP-gated ion channels (HCN), 
phosphodiesterases (PDEs) and cGMP-dependent protein kinase G (PKG) 
and thereby mediating signaling transmission (Biel et al., 1999; Francis et 
al., 2010a; Francis et al., 2010b; Pfeifer et al., 1999) (Figure 4). 
 
 
Figure 4: Effector molecules of cGMP (modified from (Pfeifer et al., 2013)). 
The second messenger cGMP mediates its effects by binding to phosphodiesterases (PDE), cGMP 
dependent protein kinases or cGMP-gates ion channels.   
 
The HCN possess an important function in the signaling pathway of retinal 
photoreceptors and olfactory receptor neurons as they regulate the influx of 
potassium and sodium (Biel et al., 1999). 
PDEs break down cGMP and cAMP to GMP and AMP, respectively. Until now 
11 members of the PDE family have been identified and they are classified 
based on their substrate specificity. The class of cAMP-specific PDEs include 
PDE 4,7 and 8 and the class of cGMP-specific PDEs include PDE 5, 6 and 9 
while other PDEs can hydrolyze both, cAMP and cGMP (1, 2, 3, 10 and 11) 
(Levy et al., 2011). PDE5 is expressed in muscle cells and PDE3 in adipose 
tissue (Boswell-Smith et al., 2006). PDE3B plays an important role in 
insulin, IGF1 and leptin signaling (Degerman et al., 1997). Overexpression 
of PDE3B in beta-cells diminishes insulin secretion and glucose tolerance in 
mice (Degerman et al., 1997).  
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The crucial mediator of cGMP effects in adipocytes is PKG (Haas et al., 
2009). PKG belongs to the family of serine/threonine kinases and two 
isoforms have been identified, PKGI and PKGII. Both kinases exhibit a 
similar structure: two cGMP binding sites and a catalytic domain (Hofmann 
et al., 2006). PKGI is predominantly localized in the cytoplasm, whereas 
PKGII is anchored to the plasma membrane (Gudi et al., 1997; Vaandrager 
et al., 1996). The 70 kDa PKGI protein is mostly expressed in vascular 
smooth muscle cells, platelets and different neurons (Hofmann, 2005). The 
main function of PKGI is relaxation of smooth muscle cells (Pfeifer et al., 
1998). In contrast, PKGII is mostly expressed in secretory epithelial cells, 
and influences bone development and growth (Pfeifer et al., 1996). 
Controversial results are described regarding the function of PKGI on 
platelet aggregation. In earlier studies it was reported that PKGI inhibits 
platelet aggregation (Massberg et al., 1999), whereas more recently, Lie et 
al. showed a novel PKG-dependent platelet aggregation pathway wherein, 
PKGI promotes platelet activation (Li et al., 2003). Studies on PKGI 
knockout mice revealed that the deletion of PKGI leads to severe 
dysfunction of vascular and intestinal function due to dysregulated smooth 
muscle cells relaxation (Pfeifer et al., 1998).  
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 Aim of the thesis 
Several research groups have shown that the NO/cGMP signaling pathway 
has a positive effect on BA differentiation and browning of WAT (Haas et al., 
2009; Mitschke et al., 2013; Nisoli et al., 2003). Results obtained from 
sGCb1 knockout mice indicate a central role of sGC in the differentiation of 
BAs (Jennissen et al., 2012). Although many effectors of the NO/cGMP 
pathway have already been analyzed for their precise roles in adipocytes, 
not much is known about the effects of sGC stimulation on adipose tissue 
and whole body metabolism. The main aim of this thesis was to identify the 
role of sGC in BA differentiation and function. This work also aims to identify 
sGC stimulators as novel pharmacological tools to develop therapies against 
obesity and its associated diseases.  
Accordingly, the following questions were raised:  
- What is the consequence of loss of sGC during BA differentiation in 
vitro and in vivo? 
- Does the pharmacological sGC stimulator (using BAY 41-5843) affect 
adipocyte differentiation in vitro? 
- What are the effects of sGC stimulation on metabolism in vivo? 
To this end, pharmacological and genetic tools (sGCb1-/- mice) were used for 
detailed in vitro and in vivo studies. 
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2 Materials and Methods 
 Materials  
 Reagents 
4-Morpholineethanesulfonic acid  Sigma-Aldrich  
Acetic acid  Sigma-Aldrich  
ADP  Sigma-Aldrich  
Agarose  PeqLab  
ammonium persulfate (APS)  Merck  
ATP  Sigma-Aldrich  
Bromphenol blue  Roth  
BSA  Roth  
BSA (essential fatty acid free)  Sigma-Aldrich  
CaCl2  Roth  
Chloroform  Roth  
Complete® EDTA-free  Roche  
Coomassie brilliant blue G-250  Merck  
Desoxy-cholic acid-Na  Sigma-Aldrich  
Digitonin  Sigma-Aldrich  
Dithiothreitol  Sigma-Aldrich  
Enhanced chemiluminescence (ECL) reagent  Amersham Biosciences  
EGTA  Sigma-Aldrich  
Eosin G  Merck  
Ethanol  Roth  
Ethidium bromide  Carl Roth GmbH  
Ethylendiamintetraacetate (EDTA)  Sigma-Aldrich  
2,2'(Hydroxynitrosohydrazano)bis-ethanime (DETA/NO) Sigma-Aldrich  
8-(4-Chlorophenylthio)guanosin-3'5'-cyclic 
monophophosphate (8-pCPT-cGMP) 
Biolog 
 
Acrylamide,Rotiphorese®Gel 30  
 
Carl Roth GmbH  
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Arteronol  Sanofi 
control diet D12450B Ssniff 
Entwicklerkonzentrat T-Matic  ADEFO-CHEMIE GmbH  
Fixierkonzentrat T-Matic ADEFO-CHEMIE GmbH  
Free Glycerol Reagent  Sigma-Aldrich  
Glucose  SERAG 
Glycerol Standard Solution  sigma-Aldrich  
HCl  Roth  
HEPES  Sigma-Aldrich  
High fat diet D12492 Ssniff 
Hydrogen peroxide  Roth  
IMMU-MOUNT  Thermo Scientific, 
Waltham 
Isopropyl alcohol (99%)  Roth  
KCl  Roth  
KH2PO4  Roth  
L-(-)-Norepinephrine bitartate salt monohydrate (NE)  Sigma-Aldrich  
LightCycler® SYBR Green I Master mix  Roche  
Mayers hemalaun  Merck  
Methanol  Roth  
MgCl 2 Roth  
Na-Citrate  Roth  
Na2HPO4  Roth  
Na3VO4  Sigma-Aldrich  
NaCl  Roth  
NaF  Roth  
NP-40  Roth  
Oil RedO  Sigma-Aldrich  
Oligomycin  Sigma-Aldrich  
Paraffin  Roth  
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Paraformaldehyde  Sigma-Aldrich  
Phosphoric acid  Sigma-Aldrich  
Precision plus All Blue Standard  BioRad 
Protease inhibitor cocktail, Complete® EDTA-free  Roche  
Proteinase K  Roche  
Roti® Phenol/C/I  Carl Roth GmbH  
Roti®-Histokitt  Carl Roth GmbH  
SDS  Sigma-Aldrich  
Skimmed milk  Sigma-Aldrich  
Sodium ascorbate  Sigma-Aldrich  
T4 DNA ligase  Invitrogen 
TaqCOREkit Qbiogen 
TEMED  Sigma-Aldrich  
Transcriptior First Strand Synthesis Kit Roche  
Triglyceride Reagent  Sigma-Aldrich  
Triton X-100  VWR  
Tween 20  Sigma-Aldrich  
Xylencyanol FF  Sigma-Aldrich  
Xylol  Sigma-Aldrich  
β-mercaptoethanol  Sigma-Aldrich  
cGMP Elisa Cayman chemical  
innuSOLV Analytik Jena AG 
   Chemicals 
All chemicals used in this thesis were purchased from following companies, 
if not further specified: Carl Roth (Karlsruhe), Calbiochem (Darmstadt), 
Gibco-Invitrogen (Karlsruhe), Merck (Darmstadt), Roche (Mannheim), 
Sigma-Aldrich (Steinheim) or VWR (Darmstadt). The water that was used 
for all the experiments was purified and distilled with an 
UV/UF system (PURELAB classic, ELGA LabWater, Celle) 
 Cell culture 
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Collagenase II  Worthington, Lakewood  
Dexamethason  Sigma-Aldrich  
DMSO  Roth  
DMEM  Gibco  
Dulbecco's modified Eagle's medium (DMEM) liquid  
(4.5 g/L D-glucose)  
Gibco  
Fetal bovine serum (FBS)  Biochrom AG  
Insulin  Sigma-Aldrich  
Isobutylmethylxanthine (IBMX)  Sigma-Aldrich  
Penicillin, Streptomycin (P/S)  Biochrom AG  
Triiodothyronine-Na  Sigma-Aldrich  
Trypan blue 0.4% solution  Sigma-Aldrich  
Trypsin-EDTA 0.05%  Invitrogen  
  
 Lab wares 
100 mm dish  Labomedic  
15 ml / 50 ml Falcon tube  Amersham Biosciences  
5 ml / 10 ml / 25 ml pipette  Sarstedt  
6-well / 12-well cell culture plate  Sarstedt  
Cell scraper  Sarstedt  
Chemiluminescence films, Hyperfilm®  Marienfeld GmbH  
Cryogenic vials  Sarstedt  
Microscope Cover Glasses  Sarstedt  
needle (26G) Millipore  
Nylon mesh  VWR  
PVDF membranes, Immobilon®P 0.45µm  Millipore  
Sterile filter 0.22 µm  BD  
Syringe 1 ml B.Braun 
   
 Equipment 
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AccuCheck with test stripes for GTT Roche 
Autoclave, Varioklav 135 T  Faust  
Casting platforms  EmbiTech  
Centrifuge, 5415R  Eppendorf  
Centrifuge, Biofuge Primo  Heraeus  
Electrophoresis chamber  Peqlab  
Electrophoresis/blotting system, Mini Trans Blot System  BioRad  
Film processor, CP100  Agfa  
Fluorescence microscope, LEICA DMIL4000 B  Leica  
Incubator, HeraCell 150  Heraeus  
Infrared camera IC060 Trotec 
Laminar air flow, HeraSafe  Heraeus  
Leica Application Suite V3  Leica Microsystems 
GmbH  
Micro plate reader, SUNRISE-BASIC TECAN  Tecan  
Microsystems GmbH, WetzlarAxioCam camera and 
AxioVision software  
Zeiss  
Microsystems GmbH, WetzlarCamera, LEICA DFC425C  Leica  
Microwave  Severin  
Neubauer counting chamber  Labomedic  
NMR device minispec Bruker Corporation 
Phenomaster device  TSE System 
Photometer, Biophotometer  Eppendorf  
Power supply, Consort E835  Peqlab  
QuantityOne® Software  BioRad  
Real-time PCR machine, StepOnePlusTM Real-Time PCR 
System  
Applied Biosystems  
Thermocycler, T1  Biometra  
Thermomixer, 5350  Eppendorf  
UV light transilluminator, GelDoc®XR  BioRad  
WetzlarMicrotome, HM335E  Microm  
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 Animal studies 
 Animal housing 
Transgenic mice used in this study were established by Prof. Friebe, 
Würzburg and were transferred to Bonn for direct use (Friebe et al., 2007). 
Newborns from sGCß1-/- mice and their littermates were used directly after 
birth. 8-week old sGCß1-/- mice and their WT littermates were bred and 
housed in Würzburg and afterwards sent to Bonn for direct experiments.  
5-week old male C57Bl/6J mice were purchased from Charles River. High fat 
diet (HFD) (60% of calories from fat, D12492) and control diet (CD) 
(D12450B) were purchased from Ssniff GmbH, Germany. 300 mg kg-1 BAY 
41-8543 were directly added to the diet as indicated.  
In the first in vivo study mice were treated for 12 weeks with CD, HFD or 
HFD+BAY 41-8543 (Figure 5).  
In the second in vivo study mice were first treated for 12 weeks with a HFD 
and then for 6 more weeks with HFD or HFD+B41-8543 or with a CD or 
CD+B41-8543 (Figure 5).  
In the third in vivo study mice were treated for 12 weeks with a CD or 
CD+B41-8543 (Figure 5).  
All mice were maintained on a daily cycle of 12 hours light (0600 to 1800) 
and 12 hours darkness (1800 to 0600), at 24 ± 1°C, and were allowed free 
access to diets and water. During the studies mice were weighed weekly.  
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Figure 5: Schematic illustration of the in vivo experiments perfomed in WT mice. 
 
 Thermography 
Infrared thermography was performed on WT and sGCß1-/- newborns 
(directly after birth). Therefore, newborns were kept for 10 min in 37°C 
separated from the mother to allow the newborn to reach same body 
temperature. Afterwards pictures were taken at ambient temperature using 
a hand-held infrared camera (IC060, Trotec GmbH). The images were 
analyzed using IC-Report software 1.2 (Trotec GmbH) (Haas et al., 2009). 
 Body composition 
In the last week of each study, body composition (lean mass, water and fat 
mass) of the mice was measured. Therefore, body weight of mice was 
measured and afterwards body composition in conscious mice was 
determined with the use of a benchtop NMR device Minispec (Bruker 
Corporation). 
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 Glucose tolerance test (GTT) 
Animals were fasted for 5 h before starting GTT. Prior to starting GTT all 
mice were weighed and then tail veins were punctured with a scalpel to 
measure starving glucose levels (time point 0) in duplicates using 
AccuCheck test stripes (Roche). The difference between both measurements 
was not more than 27 mg/dl. Then a glucose solution (0.25 g/ml) was i.p. 
injected (8 µl/g body weight) with a syringe (1 ml) and a needle (26G). 
Glucose levels were further monitored was measured 30, 60, 90 and 120 
min post injection in blood drawn from the tail vein as described above.  
 Plasma parameters 
Insulin was measured using a commercially available ELISA following 
manufacturer’s instructions (Crystal Chem). LDL and triglycerides were 
measured using a Cobas device (Roche). 
 Indirect calorimetry 
Individual oxygen consumption (VO2) and CO2 production (VCO2) were 
measured using a Phenomaster device (TSE systems) at ambient 
temperature. During measurement mice had ad libitum access to food and 
water. Furthermore, food intake and motility was recorded by the 
Phenomaster device. Energy expenditure (EE) was calculated using the 
following equation: EE [kJ/hour] = [4.44 + 1.43 x (VO2/VCO2)] x VO2 [ml 
O2/hour] x 360. 
 NE-stimulated thermogenesis 
The resting metabolic rate (RMR) was measured at 30°C for 4 h in a 
Phenomaster device individually for each mouse. After reaching an O2 
baseline, mice were weight and then NE (Arterenol, Sanofi) was injected 
subcutaneous (in the interscapular region) in a final concentration of 
1 mg/kg bodyweight after reaching a O2 baseline. Afterwards, mice oxygen 
consumption was measured for 2 h.  
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 TG measurement ex vivo 
Triglycerides (TG) are ester of fatty acids and glycerol. To detect TGs an 
enzyme coupled assay was used.  
Glycerol + ATP tà GK à G-1-P +ADP 
G-1-P+O2 à GPO à DAP+H2O2 
H2O2 + 4-AAP +ESPA à POD à Quinoneimine (colour) + H2O 
 
ATP Adenosine-5-triphosphate DAP Dihydroxyacetone phosphate 
G-1-P Glycerol-1-phosphate H2O2 Hydrogenperoxid 
ADP Adenosine-5-diphosphate POD peroxidase 
GK Glycerol kinase 4-AAP 4-Aminoantipyrine 
GPO Glycerol phosphate oxidase ESPA sodium-ethyl-N-(3sulfopropyl)m-
anisidin 
 
TG Assay reagent was prepared from free glycerol reagent and triglyceride 
reagent (Sigma) following the manufacturer’s instructions. Livers, WATi and 
muscles of mice were weighed and transferred to TGTx lysis buffer. Tissues 
were cut into small pieces, sonicated and resuspended. 
The 20 µl of the tissue suspension was added to 100 µl TG assay reagent. 
Following, the sample was measured at 540 nm in a TecanReader (Sunrise). 
The increase in absorption is directly proportional to the glycerol content. 
The Glycerol content was calculated from the resulting values and 
normalized to the wet weight of the sample. 
Glycerol content: 
(Asample-ABlank)-(AStandard-Ablank) x concentration of the standard (mg/dl) 
   TGTx lysis buffer 
   NaCl     150 nM 
   Tris-HCl      10 nM  pH 8.0 
   Triton-X 100   0.05 % 
The buffer was sterile filtered before use and then stored 
at -20°C. Before use 40 µl/ml Completeâ was added as a 
protease Inhibitor.  
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TG Assay reagent 
Free glycerol reagent    80 % 
Triglyceride reagent   20 % 
 
 Radioactive-labeled lipid uptake 
Radioactive-labeled lipid uptake was not performed in our lab, it was done 
in cooperation with the laboratory of Jörg Heeren, Hamburg. 
For this, mice were fed CD, HFD or HFD + BAY 41-8543 for 8 weeks and 
1 mg/kg BAY 41-8543 or vehicle was i.p. injected, to guarantee high 
plasma levels. Lipid uptake into tissues was measured with radioactive-
labeled triolein (PerkinElmer) which was administered by oral gavage. Mice 
were killed 2 h post injection and organs were harvested. Radioactivity was 
counted in solubilized organs by scintillation counting. To calculate total lipid 
uptake estimated organ weights were used. 
 Immunohistochemistry 
 Preparation of paraffin sections 
Paraffin embedding is a common method to cut thin sections of a variety of 
tissues. Paraformaldehyde (PFA) was used for fixation as it cross-links 
proteins while retaining their antigenicity. In order to prepare paraffin 
sections from BAT and WATi, mice were sacrificed and dissected. 
Interscapular BAT and WATi was removed, transferred to PFA fixative (4 % 
PFA in PBS) and incubated at 4°C for 2 days. Afterwards, tissue samples 
were dehydrated by successive incubations in ethanol of ascending 
concentrations (50 %, 70 %, 96 %, 100 %) at RT for 30 min each. 
Subsequently, samples were incubated in xylol 3 times for 10 min at RT and 
placed in paraffin 3 times for 1 h at 60°C. Tissue samples were embedded 
with fluid paraffin (60°C) and paraffin blocks were stored afterwards at RT. 
5 µm thick sections of the embedded tissues were cut using a microtome 
(Microm). Slides were dried at RT and stored at RT.  
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 Hematoxylin/Eosin (H/E) staining  
H/E staining is a widely used technique to visualize numerous tissue 
structures. Cell nuclei are stained in blue by hematoxylin whereas the 
cytoplasm and connective tissue appear in a variety of pink nuances, 
caused by the eosin staining. H/E stains were performed at RT. Paraffin 
sections were incubated for 2 min in xylol (deparaffinization), then in 
ethanol of descending concentrations (100 %, 96 %, 70 %, 50 %) and 
finally in water (rehydration) 2 min each. Afterwards, slides were treated 
with hematoxylin (Mayers hemalaun, Merck) for 1 min, washed in water for 
15 min. Then slides were stained with eosin (Eosin G, Merck) for 1 min and 
again washed in water. Sections were dehydrated in ethanol of ascending 
concentrations (70 %, 90 %, 96 %, 100 %) and xylol for 2 min each and 
mounted with Roti®-Histokitt (Carl Roth GmbH). Images were taken using 
a LEICA DMI4000 B microscope (Leica Microsystems GmbH) equipped with 
a LEICA DFC425 C camera (Leica Microsystems GmbH). Adipocyte diameter 
was measured using ImageJ. 
 UCP1 staining of paraffin sections 
Four-micrometer paraffin-embedded sections from interscapular BAT region 
from newborn sGCb1-/- mice and their WT littermates as well as BAT and 
WATi from adult mice were blocked with 2 % normal chicken serum–TBS 
(tris-buffered saline) for 30 min at RT and washed three times with 1 % 
BSA–TBS. Primary antibody against UCP (Sigma-Aldrich) 1, diluted 1:50, 
was applied overnight at 4°C temperature. After washing three times with 
PBS-T, secondary antibody against rabbit (SignalStain Boost IHC, Cell 
Signaling) was applied for 1 h at RT and developed with DAB Kit (Vector 
Laboratories) according to the manufacturer’s instructions. After DAB 
development, sections were incubated with Hematoxylin for 10 sec and 
covered with Roti Histo-Kitt (Roth). Sections were dehydrated in ethanol of 
ascending concentrations (70 %, 90 %, 96 %, 100 %) and xylol for 2 min 
each and mounted with Roti®-Histokitt (Carl Roth GmbH). Images were 
taken using a LEICA DMI4000 B microscope (Leica Microsystems GmbH) 
equipped with a LEICA DFC425 C camera (Leica Microsystems GmbH).   
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 Cell culture 
 Isolation of mesenchymal stem cells 
The mesenchymal stem cells (BAT-MSC) were isolated from interscapular 
BAT pads of newborn sGCß1-/- mice and their WT littermates as previously 
described (Haas et al., 2009). After isolation of the fat pads they were 
transferred to the isolation buffer. This suspension was shaken every 5 min 
for in total 30 min in a water bath with 37°C. The tissue carryover was 
removed by filtration through a 100 µM nylon mesh (Millipore). After 
filtration the BAT-MSC suspension was placed on ice for 30 min. After this 
time, 3 phases of the BAT-MSC suspension are obtained and the middle 
phase was again filtered through a 30 µM nylon mesh. After filtration the 
suspension was centrifuged for 10 min at 700 g. The pelleted cells were 
resuspended in culture media. The cells of one newborn were plated in one 
6-well and incubated at 37°C and 5 % CO2.  
   Isolation buffer    
   NaCl    123 mM 
   KCl        5 mM 
   CaCl2     1.3 mM 
   Glucose       5 mM 
   HEPES   100 mM 
All substances were solved in water, the pH was adjusted 
to 7.4. The buffer was and then sterile filtered and 
stored at 4°C. 
Shortly before use, following substances were added 
BSA      1.5 % 
Collagenase     0.2 % 
and again sterile filtered. 
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Culture media  
DMEM Glutamax I +4500mg/dl Glucose 
FBS    10 % 
P/S      1 % 
Insulin    4 nM 
Triiodothyronine-Na  4 nM 
HEPES           10 nM 
Sodium ascorbate       25 µg/ml 
 
  Immortalization of primary BAT-MSCs 
Primary BAT-MSCs were immortalized 24 h after isolation with a lentivirus 
which contains the large T-antigen expressing the Simian Virus 40 (SV40) 
under control of the phosphoglycerate kinase (PGK) promoter. After 
infection the cells were cultivated with growth media at 37°C and 5 % CO2. 
When the cells reached confluence they were splitted 1:5. All experiments 
were done with cells of the passage 4. 
   Growth media 
DMEM Glutamax I +4500 mg/dl Glucose 
FBS    10 % 
P/S      1 % 
 
  Cryo conservation and thawing of cells 
The cells were cultured in growth media at 37°C and 5 % CO2 as described 
above. The confluent cells were washed with PBS and to detach the cells 
they were incubated for 5 min with Trypsin-EDTA at 37°C and 5 % CO2. The 
detached cells were resuspended in growth media and centrifuged for 5 min 
at 1000 rpm. 
Afterwards the cell pellet was resuspended in freezing medium. The cells 
were transferred to a cryo vial and placed on ice for 15 min. Afterwards, the 
cryo vials were stored at -80°C for 24 h before transferring them to -150°C 
for long-term storage. 
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freezing medium 
DMEM Glutamax I +4500 mg/dl Glucose 
FBS     10 % 
P/S       1 % 
Dimethyl sulfoxide(DMSO)  10 % 
The cryo-preserved cells were quickly placed in the water bath at 37°C. 
Afterwards the 10-fold volume of pre-warmed growth media was added to 
the cells and centrifuged 5 min at 37°C. The cell pellet was resuspended in 
growth media and the cell number was determined using a Neubauer 
chamber. After adjustment of the cell number, cells were plated in 6–well 
plates.  
 Adipogenic differentiation of brown adipocytes 
The SVF of brown adipocytes was seeded at a density of 1.8x105 in each 
well of a 6-well plate (d-4). After 48 h the medium was changed to 
differentiation media (d-2). On day 0 cells were confluent and the media 
was changed to induction media for additional 48 h. Starting from d2 
onwards, the media was changed every second day with differentiation 
media until BAT-MSCs were differentiated to mature BAs (d7). 
Differentiation media 
DMEM Glutamax I +4500 mg/dl Glucose 
FBS    10 % 
P/S      1 % 
Insulin    4 nM 
Triiodothyronine-Na  4 nM 
 
Induction media 
DMEM Glutamax I +4500 mg/dl Glucose 
FBS    10 % 
P/S      1 % 
Insulin    4 nM 
Triiodothyronine-Na  4 nM 
Dexamethasone   1 µM 
IBMX          0.5 mM 
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2.4.4.1 Substances  
As indicated in respective experiments, cells were treated with following 
substances, which were added freshly after every medium change. 
PKG activator  
As a PKG activator 8-pCPT-cGMP was used. The stock solution was 10 mM 
solved in water and diluted in the media to an end concentration of 200 µM 
in the well.  
NO donor 
The NO donor 2,2′-(Hydroxynitrosohydrazono)bis-ethanimine (DETA/NO) 
was used in the experiments. The substance has a half life of 20 h when 
incubated at pH 7.4 and 37°C. Shortly before the media change DETA/NO 
was dissolved in a 10 mM NaOH solution and the stock was 10 mM as 
diluted to the requested concentration in the media. 
sGC stimulator 
BAY 41-8543 (gift from BAYER HealthCare GmbH) was used as sGC 
stimulator to activate the enzyme. The concentration which was used for 
cell culture experiments was 3 µM. The stock solution was 3 mM solved in 
DMSO and then diluted in the media.  
 cGMP Elisa 
The cGMP levels in brown adipocytes were measured by EIA (Cayman 
Chemical) following the manufacturer’s instructions. Therefore, sGCb1-/- cells 
and WT cells were differentiated to mature adipocytes in 6-well plates. 
Mature adipocytes were acutely treated either with 3 µM BAY 41-8543 or 50 
µM DETA/NO or a combination of both substances for 15 min at 37°C and 
5 % CO2. After washing with PBS, cells were lyzed with 200 µl 0.1 M 
HCl/well for 15 min at RT. Afterwards cells were scraped with a cell scraper 
from the plate and centrifuged at 600 g for 5 min. Supernatants were used 
to perform the enzyme immunoassays. Results were normalized to protein 
content of the cells using the Bradford protein assay.  
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 Oil RedO staining of mature BA 
Oil RedO staining was used to visualize the lipid droplets of the cells. During 
differentiation of adipocytes the lipids accumulate to lipid droplets and these 
lipid droplets can be stained with Oil RedO. Therefore, the differentiated 
adipocytes where washed three times with PBS and then cells were fixed 
with 4 % Paraformaldehyde (PFA) for 15 min at RT. Later, the PFA was 
washed out with PBS and cells were incubated with Oil RedO solution (3 
mg/ml in isopropyl alcohol) for 4 h at RT and finally washed three times 
with water. 
   Oil RedO stock solution  
   Isopropyl alcohol (99%)  100 ml 
   Oil RedO        0.5 g 
dissolved overnight on a magnetic stir bar and stored at 
RT.  
   Oil RedO working solution  
   Water         4 ml 
   Oil RedO stock solution      6 ml 
Filtered two times through a paper filter the day of use.  
 
 Quantification of triglyceride accumulation in adipocytes 
Detailed explanation of this experiment is shown in 2.2.8.  
Free glycerol reagent and triglyceride reagent were used following the 
manufacturer’s instructions. The BAT-MSC were differentiated to mature 
brown adipocytes (d7) and then washed with PBS. 400 µl TGTx lysis buffer 
was added to the cells on day 7. Subsequently, the cells were frozen at       
-80°C und stored there until the assay was performed. 
After the cells were thawed on ice, the adipocytes were scraped from the 
plate and resuspended. Subsequently, the suspension was centrifuged for 
10 min at 14 000 rpm and 4°C. After centrifugation 2 µl of the supernatant 
was used to measure the protein content with the aid of the Bradford assay 
(2.5.2).  
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The pellet was resuspended and 20 µl of the suspension was added to 100 
µl TG assay reagent. Following, the sample was measured at 540 nm 
(TecanReader, Sunrise). The increase in absorption is direct proportional to 
the glycerol content. The measured glycerol content was normalized to the 
protein content.  
 Lipolysis 
Lipolysis is a process where TGs are enzymatically hydrolyzed to free fatty 
acids and glycerol. The release of stored TGs in adipocytes is controlled 
through lipolytic hormones like for example catecholamines. To detect the 
lipolytic activity in BA, cells were differentiated in 6-well plates until d7 and 
then washed three times with lipolysis media (37°C). After the washing step 
the cells were incubated with 800 µl lipolysis media for 2 h at 37°C and 5 % 
CO2. As a positive control cells were stimulated with 10 µM norepinephrine 
(NE). After the incubation time 40 µl of the supernatant was used for the 
assay. The supernatant was mixed with 60 µl of the free glycerol reagent 
and incubated for 5 min at 37°C. As control only the lipolysis media was 
used and a standard glycerol reagent was used to calculate the glycerol 
concentration in the cells. All samples were pipetted in a 96-well plate and 
measured in a TecanReader (Sunrise) at 540 nm. The glycerol release was 
normalized to the protein content of the cells, which was determined using 
Bradford assay (see 2.5.2).  
   Lipolysis media 
   DMEM (4.5 g/l D-glucose, -pyruvate, without phenol red) 
   BSA free fatty acid free  2 %  
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 Biochemical methods 
 Preparation of total protein lysates from adherent cells and tissue 
Mature BA were washed with ice cold PBS and following 200 µl lysis buffer 
(radio immunoprecipitation (RIPA)) was added to each wells. With the aid of 
the lysis buffer and a cell scraper the cells were detached from the plate. 
The lysate was centrifuged at 4°C and 14.000 rpm for 20 min. The 
supernatant was transferred to a fresh tube. The protein content was 
detected by Bradford assay. The protein content was adjusted and 
afterwards the calculated volume of 3x laemmli was added (Laemmli, 
1970). The adjusted proteins were cooked for 5 min at 95 °C (Thermoblock) 
and either used directly or frozen at -20°C until they were used for the 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  
Tissue protein lysates were generated by using a small piece of BAT and 
sonicated in 250 µl lysis buffer (radio immunoprecipitation (RIPA)) until the 
suspension was homogeneous. Afterwards, the lysate was centrifuged at 
4°C and 14.000 rpm for 20 min. And  
   Lysis buffer (RIPA) 
   TrisHCl     10 mM 
   NaCl     150 mM 
   NP-40           1 % pH 7.4 
   sodium dodecyl sulfate (SDS)    0.1 % 
   sodium deoxycholate        1 % 
   The buffer was sterile filtered and stored at 4 °C. 
   Before use, following substances were added 
   Completeâ EDTA free  40 µl/ml 
   NaF        10 mM 
   Na3VO4         1 mM 
     
3 x laemmli buffer 
   TrisHCl    125 mM 
   Glycerol        20 % 
   SDS         17 %  
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   Bromophenol blue   0.015 % 
   Dissolved in water and stored at -20°C. 
Before use, 5 % b-mercaptoethanol was added.  
 Determination of protein content using Bradford 
The protein content in BA and of the BAT tissue was calculated using the 
Bradford method (Bradford, 1976). The protein concentration of the 
investigated lysates was determined in a photometer using a defined BSA 
standard curve. Therefore, 2 µl cell/tissue lysate and 98 µl 0.15 M NaCl 
solution was mixed, 1 ml coomassie solution was added and incubated for 2 
min. After the incubation time the absorption was measured at 595 nm in a 
TecanReader (Sunrise).  
   Coomassie solution 
   Coomassie brilliant blue G250 0.01 % 
   EtOH          5 % 
   Phosphoric acid      8.5 %  
All substances were dissolved in water and stored at 4°C 
protected from light. 
 
 Gel electrophoresis of proteins (SDS-PAGE) 
Using SDS-PAGE, denatured proteins were separated according to their 
molecular weight. Therefore, first the resolving and afterwards the stacking 
gel were poured between two glass plates (BioRad). The two glass plates 
were fixed in a casting stand and the resolving gel was poured. After 20 min 
the gel was polymerized. Afterwards the stacking gel was poured on top of 
the resolving gel and a comb was inserted and after polymerization 
removed. The gel was inserted in an electrophoresis chamber with running 
buffer and then the samples were loaded into the pockets of the stacking 
gel. In each pocket either 15 µg or 50 µg were loaded, depending on the 
protein analyzed. The proteins were separated at 100 V and 300 mA for 
2.5 h.  
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Table 1: Different concentrations of SDS-PAGE gel compounds 
Resolving gel  Stacking gel 
 10 % 15 %   4 % 
Water 4 ml 2.3 ml  Water  3.4 ml 
Rotiphorese®Gel 30 3.3 ml 5 ml  Rotiphorese®Gel 30 0.83 ml 
1.5 M TrisHCl pH 8.8 2.5 ml 2.5 ml  1.5 M TrisHCl pH 6.8 0.63 ml 
APS 20% 0.05 ml 0.05 ml  APS 20 % 0.025 ml 
TEMED 0.004 ml 0.004 ml  TEMED 0.005 ml 
 
   10 x SDS-PAGE running buffer 
   Tris    250 mM 
   Glycine         2 M 
   SDS       0.1 % 
   Dissolve all substances in water and store at RT. 
 
 Western blotting  
After the SDS-PAGE the separated proteins were transferred to a 
nitrocellulose membrane. This transfer is a wet electrophoresis according to 
Towbin (Towbin et al., 1979). To do so, the gel was taken out from the 
electrophoresis chamber and after separating the stacking gel was 
removed. The gel, nitrocellulose membrane and whatman paper were 
laminated without air bubbles in sandwich principle. The sandwich was 
transferred to a chamber with transfer buffer and the electron transfer 
according to protein size of the analyzed protein, as shown in the following 
table. 
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Table 2: Transferring conditions of proteins with different sizes 
Protein size Volt Ampere Time temperature 
15-30 kDa 100 V 300 mA 45 min With ice 
package 
30-75 kDa 100 V 300 mA 1h 15 min With ice 
package 
 
Transfer buffer 
   10 x SDS.PAGE running buffer  10 % 
   Methanol    20 % 
   Dissolve in water and store at 4°C. 
 
 Immunodetection  
After the protein transfer the membrane was blocked in blocking solution for 
1 h, to block unspecific binding sites. Afterwards, the membrane was 
washed 3 times with TBS-T and then incubated with the primary antibody 
over night at 4°C.  
Table 3: List of primary antibodies for immunblotting 
Primary antibody Company  Dilution 
aP2 Santa Cruz, Santa Cruz, USA 1/1000 
PPARg Santa Cruz, Santa Cruz, USA 1/1000 
Cytochrome C BD Bioscience, Franklin Lakes, USA 1/1000 
UCP1 Sigma 1/500 
sGCα1 Sigma 1/1000 
sGCα2 Abcam 1/500 
sGCβ2 Cayman 1/1000 
β-Actin Santa Cruz, Santa Cruz, USA 1/1000 
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Tubulin Dianova, Hamburg, Germany 1/1000 
 
Table 4: List of secondary antibodies for immunblotting 
Secondary antibody Company dilution 
Rabbit-HRP Cell-signaling, Danvers, USA 1/5000 
Mouse-HRP Dianova, Hamburg, Germany 1/10000 
Goat-HRP Chemicon, Schwalbach, Germany 1/5000 
The day after, the membrane was washed 3 times 5 min with TBS-T. 
Afterwards, the membrane was incubated with the secondary antibody for 
1 h at RT. After this, the membrane was again washed 3 times 5 min with 
TBS–T. The immunoreactivity bands were detected with the aid of 
chemiluminescence. The principle of chemiluminescence is the reaction of 
the ECL solution with the HRP-conjugated secondary antibody and then the 
band can be detected. For this, the membranes were incubated with ECL 
solution for 2 min and then developed in the dark room using 
ECLHyperfilm™. The film was scanned with the aid of a scanner and then 
quantified with the software QuantityOne (BioRad). After detection of one 
desired protein, antibodies were stripped off the membrane with stripping 
solution for 30 min. After a 5 min wash with PBS, the whole 
immunodetection procedure could be repeated on the same membrane to 
detect different proteins.  
   10x TBS 
   Tris     100 mM 
   NaCl        1.4 M 
Dissolved in water and the pH was adjusted to 8.0 and 
afterwards stored at RT. 
TBS-T 
10 x TBS        10 % 
Tween-20       0.1 % 
Dissolved in water and stored light protected at RT. 
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Blocking solution 
Milk powder         5 % 
Dissolved in TBS-T and then stored at 4°C. 
Stripping solution 
Glycine       2.5 M 
SDS          1 % 
Dissolved in water, pH adjusted to 2 and stored at RT.  
 
 Molecular biological methods 
 Phenol/chloroform extraction of genomic DNA 
For the isolation of mitochondrial DNA from BAs and tissue following 
protocol was used. For cells, 1 ml Proteinase K buffer was added to one 6-
well, cells were scraped from the plate and transferred to a fresh tube. 
These tubes were incubated at 55°C and 550 rpm overnight in a 
Thermomixer. The day after 500 µl phenol/chloroform (Rothi®-phenol, Carl 
Roth GmbH) was added and shaken carefully. Afterwards, the DNA solution 
was centrifuged 10 min at 13000 rpm. The upper part of the solution was 
transferred to a fresh tube and 500 µl chloroform was added and shaken 
carefully. The solution was again centrifuged 10 min at 13000 rpm. After 
centrifugation two phases were visible, the upper one was transferred to a 
new tube. In this new tube 800 µl isopropanol was added and the tube was 
inverted to precipitate the DNA. After an additional centrifugation of the 
solution for 10 min at 13000 rpm and a washing step with 75 % EtOH, the 
pellet was dried at RT. Finally, the DNA was dissolved in 50 µl or more 
water and the concentration was measured at NanoDrop.  
   Protein Kinase K buffer 
   TrisHCl   100 mM 
   NaCl    200 mM 
   EDTA        5 mM 
   SDS       0.2 % 
   Proteinkinase K       0.1 mg/ml 
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The amount of mtDNA (mt-Co1, mt-Nd1, and mt-Cytb) was normalized to 
the amount of chromosomal DNA (H19).  
 Isolation of ribonucleic acid (RNA) from differentiated adipocytes and 
tissues 
The isolation of RNA from cells and tissues was performed with the aid of 
InnuSOLV reagent. Therefore, 1 ml InnuSOLV reagent was added to the 
cells or minced tissues and 200 µl chloroform was added. The mix was 
shaken powerful for 15 sec.  
Afterwards, the solution was incubated for 5 min at RT and centrifuged for 
10 min at 13000 rpm and 4°C. After the centrifugation three phases were 
visible and the middle one was transferred to a new tube. Afterwards, 
500 µl isopropanol was added, shaken and centrifuged for 10 min at 13000 
rpm and 4°C. The resulting RNA pellet was washed with 75 % ethanol, dried 
and dissolved in DEPC-water. To determine the RNA concentration, the 
samples were measured at the NanoDrop.  
For the reverse transcription polymerase chain reaction (RT-PCR) 500 ng 
RNA were reverse transcribed to complementary DNA (cDNA) with the aid 
of transcription first strand synthesis kit (Roche). The master mix was used 
as described in the manufacturer’s instructions.  
 Polymerase chain reaction (PCR) 
For the quantitative determination of mRNA levels, quantitative real-time 
(qRT) PCR using SYBR green was performed on the cDNA samples. SYBR 
Green is a fluorescent dye, which intercalates in the double strained DNA. 
This interaction leads to a fluorescent signal, which is proportional to the 
amount of DNA. The SYBR Green qRT-PCRs were performed with the aid of 
LightCycler® SYBR Green I master Mix (Roche) or Power SYBR Green PCR 
Master Mix (AppliedBiosystems) and the following program and primer 
sequences. 
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SYBR Green qRT-PCR 
   cDNA        5 µl 
   forward primer (5 pmol/µl) 0.5 µl 
   reverse primer (5 pmol/µl) 0.5 µl 
   SYBR Green I Master Mix     5 µl 
 
SYBR Green qRT-PCR program for mt DNA 
Steps Time (seconds) Temperature (°C) 
1 900 95 
2 10 95 
3 20 33 
4 30 72 
5 5 82 
6 60 25 
Steps 2 to 5 were repeated 40 time 
Table 5: List of mitochondrial pirmer for qRT-PCR 
 
 
 
 
SYBR Green qRT-PCR program for thermogenic markers 
Steps Time (seconds) Temperature (°C) 
1 600 95 
2 10 95 
3 15 72 
4 90 72 
5 1 82 
Steps 2 to 5 were repeated 40 times  
 
  
Primer Forward reverse 
Nd1 AATCGCCATAGCCTTCCTAACAT GCCGTCTGCAAATGGTTGTAA 
Cytb TTCTGAGGTGCCACAGTTATT GAAGGAAAGGTATTAGGGCTAAA 
Co1 CCCAATCTCTACCAGCATC GGCTCATAGTATAGCTAGGAG 
H19 GTACCCACCTGTCGTCC GTCCACGAGACCAATGACTG 
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Table 6: List of murin primer for qRT-PCR 
Primer Forward reverse 
ATPsyn AGTTGGTGTGGCTGGATCA GCTGCTTGAGAGATGGGTTC 
CD36 TGGCCAAGCTATTGCGACAT AGGCATTGGCTGGAAGAACA 
Cpt1b GGCACCTCTTCTGCCTTTAC TTTGGGTCAAACATGCAGAT 
Cox8b GAACCATGAAGCCAACGACT GCGAAGTTCACAGTGGTTCC 
Glut-4 GACGACGGACACTCCATCTG AGCTCTGCCACAATGAACCA 
Dio2 GCGATGGCAAAGATAGGTGA GAATGGAGCTGGGTGTAGCA 
HPRT ACATTGTGGCCCTCTGTGTGCTCA CTGGCAACATCAACAGGACTCCTCGT 
HPRT(ABI) GTCCCAGCGTCGTGATTAGC TCATGACATCTCGAGCAAGTCTTT 
Lpl AGCAGCAAGACCTTCGTGG TCTCTCTTGTACAGGGCGGC 
Nrf1 TGTGGCAACAGGGAAGAAACGGAA TCCGTAATGCCTGGGTCCATGAAA 
PGC-1α GCACACACCGCAATTCTCCCTTGTA ACGCTGTCCCATGAGGTATTGACCA 
PPARδ ACTGCAGCCCCCTATAGT GGATCAGTTGGGTCAGTGGG 
Slc27a3 TGGATTTGGTTCGGACTGGC CTGGCTCATCCACTTGGTCT 
ß3AR ATCTTCTCTCTGTGCTGGCTGCCCT CATCGGTTCTGGAGCGTTGGAGAGT 
UCP1 (ABI) TAAGCCGGCTGAGATCTTGT GGCCTCTACGACTCAGTCCA 
VEGF GGAGATCCTTCGAGGAGCACTT GGCGATTTAGCAGCAGATATAAGAA 
 
   Power SYBR Green qRT-PCR 
   cDNA        4 µl 
   forward primer (5 pmol/µl) 0.5 µl 
   reverse primer (5 pmol/µl) 0.5 µl 
   SYBR Green I Master Mix     5 µl 
 
  SYBR Green qRT-PCR program for ABI primer 
Steps Time (seconds) Temperature (°C) 
1 600 95 
2 15 95 
3 60 60 
4 1 25 
Steps 2 to 3 were repeated 40 times  
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The relative quantification of the mRNA level was performed with the aid of 
the DDCt method. The PCR products increase exponential until they reached 
a plateau. Ct value is defined as the time when the fluorescence is 
exceeding the background. HPRT or GAPDH were used as housekeeper 
genes.  
 Genotyping sGCb1-/- and WT mice 
For genotyping, a small biopsy of the ear punch was digested in 88 µl water 
plus 10 µl PCR buffer with MgCl2 and 2 µl proteinase K at 55°C and 600 rpm 
in a thermomixer (Eppendorf) overnight. Afterwards DNA was isolated as 
described in 2.6.1. For PCR, 1 µl DNA was used. 
Primer 
 IoxP-b1-U1  5’- AAGATGCTGAAGGGAAGGATCG-3’ 
 IoxP-b1-L1  5’- CAGCCCAAAGAAACAAGAAGAAAG-3’ 
 del -b1-L1   5’- GATGTGGGATTGTTTCTGAGGA-3’ 
 
   Genotyping PCR program  
Steps Time (seconds) Temperature (°C) 
1 180 94 
2 60 95 
3 45 60 
4 420 72 
Steps 2 to 4 were repeated 30 times  
Bands detected for WT mice were 680 bp and sGCb1 knockout mice 830 bp.  
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 Agarose gel electrophoresis 
Agarose gel electrophoresis is used for separating, identifying and purifying 
DNA fragments. For gel preparation, 0.8 % agarose was added to 1x Tris-
acetic acid-EDTA (TAE) buffer and boiled in a microwave (Severin). 
Afterwards 800 ng/ml ethidium bromide was added and the solution was 
poured into casting platforms (EmbiTech). After polymerization at RT, the 
gel was placed in an electrophoresis chamber (Peqlab) containing 1x TAE 
buffer. For electrophoretic separation, 6x loading dye was added to the PCR 
products and loaded on the agarose gel. Electrophoresis was performed at 
100 V. DNA bands were visualized using a UV light transilluminator 
(GelDoc®XR, BioRad) at 366 nm using QuantityOne® Software (BioRad). 
    1x TAE buffer 
     Tris    100 mM 
acetic acid    0.11 %  
Na2-EDTA       1 mM  
 
6x loading dye 
 
Ficoll Typ 400       18 %  
EDTA       0.12 mM  
Bromphenol blue     0.15 %  
Xylencyanol FF     0.15 % 
in 1x TAE buffer  
 Statistics 
Statistical analysis was performed with GraphPad prism 5 software. Two-
tailed Student’s t-tests or analysis of variance (ANOVA) with Bonferroni 
post-hoc tests for multiple comparisons were used as indicated under the 
figures. P values below 0.05 were considered significant. All data are 
represented as mean ± SEM. 
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3 Results 
 Expression pattern of sGC in pre- and mature adipocytes 
To study the expression of sGC in BAs, SVF from WT and sGCβ1-/- mice 
were isolated and the containing MSC and preadipocytes were 
differentiated into mature BAs using the established protocol described 
above (2.4.4). The protein expression level of all three sGC subunits was 
determined by Western blot analysis. sGCβ1-/- cells were used to study 
potential differences in the expression pattern compared to WT cells. 
Surprisingly, expression of β1 subunit was absent in WT preadipocytes. 
Mature brown WT adipocytes express all three sGC subunits, as monitored 
by detection of sGCa1, sGCa2 and sGCb1. Moreover, expression levels of all 
subunits were highly increased following maturation. As expected, sGCβ1-/- 
cells do not possess the β1 subunit (Figure 6). In comparison to WT cells, 
there is a lower expression of sGCα1 and sGCα2 in mature brown sGCβ1-/- 
adipocytes (Figure 6).  
 
Figure 6: sGC is highly expressed in mature brown adipocytes.  
Western blot analysis of the expression levels of the distinct sGC subunits (sGCα1, sGCα2 and sGCβ1) in 
preadipocytes and adipocytes from WT and sGCβ1-/- mice. Tubulin was used as loading control.  
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 sGCβ1 deficiency leads to alteration in body composition of newborn 
and adult mice       
 sGC is crucial for body temperature of newborn mice 
The main function of BAT is non-shivering thermogenesis in newborns 
(Barnard, 1977), however only little is known about this effect in sGCβ1-/- 
mice. The impact of sGC deficiency on BAT thermogenesis was 
investigated in newborn sGCβ1-/- mice and their WT littermates. Therefore, 
the surface temperature of the interscapular region (where BAT is located) 
was measured by using infrared thermography. Furthermore, the BAT 
weight and UCP1 expression in BAT were determined.  
 
Figure 7: sGC is crucial for thermogenesis in newborn mice. 
(a) Representative thermographic image of newborn WT and sGCβ1-/- mice. (b) Interscapular 
temperature of WT and sGCβ1-/- newborn mice measured with infrared thermography. (c) Weight of 
brown adipose tissue related to the whole body weight. (d) UCP1 mRNA expression in brown adipose 
tissue of newborn mice. (e) Representative images of brown adipose tissue sections stained with UCP1 
(brown color), scale bar 100 µM. (b, c, d): n=8-9 mice per genotype. All data are represented as 
mean ± SEM and statistical testing was performed using Student`s t-test, ***p<0.005.  
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The surface temperature of the sGCβ1-/- mice was significantly reduced by 
2.0 °C compared to WT mice (Figure 7a,b). Furthermore, BAT weight was 
significantly reduced by 50.1 % in comparison to WT littermates (Figure 
7c). Interestingly, UCP1 mRNA expression was diminished by 83.5 % in 
sGCβ1-/- mice compared to WT mice (Figure 7d). Histological examination 
of BAT revealed a reduction of UCP1 in sGCβ1-/- mice compared to the WT 
littermates (Figure 7e). Together, these results indicate that sGC is crucial 
for BAT function in newborn mice. 
 Loss of sGC leads to a reduction of adipose tissue in adult mice 
The influence of sGC on the amount of white and brown adipose tissue was 
analyzed in 8-week old sGCβ1-/- mice and their WT littermates. Body 
weight of sGCβ1-/- mice was significantly reduced by 21.1 % in comparison 
to WT littermates (Figure 8a). 
Deletion of sGCβ1-/- significantly reduced BAT weight by 6.0 ± 0.7 mg/g 
bodyweight compared to WT littermates (Figure 8b). As cGMP is also 
crucially involved in the differentiation of WAs (Mitschke et al., 2013), 
WATi of sGCβ1-/- mice and WT littermates was analyzed graphimetrically 
and histologically. In sGCβ1-/- mice weight of WATi was significantly 
reduced in comparison to WT littermates (Figure 8c). Histology did not 
reveal any obvious differences in WATi morphology between WT and 
sGCβ1-/- mice (Figure 8d). In adult mice, sGC deficiency resulted in weight 
decrease of BAT and WATi whereas the morphology of the latter remained 
unchanged. Importantly, sGCβ1-/- mice exhibit severe phenotypes including 
impaired smooth muscle function, intestinal abnormalities and increased 
blood pressure (Friebe et al., 2007). Therefore, only few adult mice were 
available for analysis and the metabolic phenotype of adult mice might be 
affected by the wide spread alterations observed in the knockout mice.   
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Figure 8: Loss of sGC leads to a reduction of adipose tissue weight in adult mice. 
Analyses of 8-week old WT and sGCb1-/- mice on (a) Body weight. (b) Weight of BAT WT and sGCb1-/- 
mice related to the whole body weight. (c) Weight of WATi related to the whole body weight. (d) 
Representative image of WATi stained with hematoxylin and eosin. n=6 mice per genotype, scale bar 
100 µM. All data are represented as mean ± SEM and statistical testing was performed using Student 
t-test *p<0.05; **p<0.01.  
 
 sGC deficiency impairs BA function 
 Deletion of sGC influences cGMP production and lipid accumulation 
Furthermore, the role of sGC on differentiation and function of BAs was 
investigated in more detail. Therefore, SVF from sGCβ1-/- mice and their 
WT littermates were isolated and differentiated into mature BAs. The 
addition of 200 µM cGMP has been shown to increase differentiation of BAs 
(Haas et al., 2009).  
In order to investigate the impact of sGCβ1 on cGMP production, cGMP 
concentration was measured in mature sGCβ1-/- and WT BAs. The NO 
Donor DETA/NO was used to stimulate sGC. After 15 min incubation with 
DETA/NO the cGMP level was significantly (10.2 fold) increased in 
comparison to untreated WT cells (Figure 9a). 
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Figure 9: sGC mediated cGMP production and lipid accumulation. 
(a) Basal and NO-stimulated cGMP content in WT and sGCb1-/- brown adipocytes, n=5 independent 
cell cultures. (b) Brown WT and sGCb1-/- adipocytes differentiated in absence or presence of 200 µM 
8-pCPT-cGMP and then stained with Oil RedO. (c) Intracellular triglyceride (TG) content in WT and 
sGCb1-/- cells differentiated in absence or presence of 200 µM 8-pCPT-cGMP; n=5 independent cell 
cultures. All data are represented as mean ± SEM and statistical testing was performed using 
Student t-test *p<0,05; ***p<0.005.  
To test whether cGMP is produced in the absence of sGCβ1, cGMP 
production was measured in sGCβ1-/- BAs. In contrast to WT cells treated 
with DETA/NO, sGCβ1-/- cells produced significantly lower amounts of cGMP 
(a). Additionally, the acute treatment of sGCβ1-/- cells with 50 µM DETA/NO 
did not significantly increase the cGMP content (Figure 9a).  
Chronic treatment with 200 µM cGMP throughout differentiation increased 
the lipid content in WT cells as shown by Oil RedO staining (Figure 9b). In 
comparison to untreated WT cells, untreated sGCβ1-/- cells exhibited a 
decreased lipid content. sGCβ1-/- cells treated chronically with 200 µM 
cGMP differentiated more efficiently than sGCβ1-/- cells without treatment 
(Figure 9b). For quantification, TG content of BAs was measured. 200 µM 
cGMP increased the TG content in WT cells by 2.4 ± 0.6 fold in comparison 
to untreated WT cells (Figure 9c). In contrast, sGCβ1-/-cells stored 41.0 % 
less TG than untreated WT cells (Figure 9c). Chronic treatment of sGCβ1-/-
cells with 200 µM cGMP throughout differentiation increased the TG 
content 1.5 ± 0.3 fold compared to untreated WT cells (Figure 9c). In 
comparison to untreated sGCβ1-/-cells, sGCβ1-/-cells treated with cGMP 
stored 2.6 fold more lipids. These data demonstrate, that deletion of 
sGCβ1-/- leads to an impaired TG storage, which could be rescued by 
addition of cGMP.  
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3.3.1.1 Deletion of sGC affects the adipogenic and thermogenic program 
The influence of sGC deficiency on the adipogenic and thermogenic 
program of BAs was analyzed in differentiated WT and sGCβ1-/- BAs in 
vitro. PPARγ and aP2 were used as adipogenic markers whereas UCP1 and 
cytochrome c (Cytc) were used as marker for the thermogenic program. 
Western blot analysis showed that cGMP increased the PPARγ abundance 
to 694.0 ± 168.1 % in comparison to untreated WT cells (Figure 10a). In 
contrast to un treated WT cells, protein level of PPARγ was downregulated 
by 60.8 % in untreated sGCβ1-/- cells (Figure 10a). Treatment of sGCβ1-/- 
cells with cGMP significantly increased PPARγ expression by 453.6 ± 
58.0 % compared to untreated WT cells (Figure 10a). In comparison to 
untreated sGCβ1-/- cells, sGCβ1-/- cells treated with cGMP significantly 
increased the expression of PPARγ (11.6 fold) (Figure 10a). However, 
PPARγ protein levels in sGCβ1-/- cells treated with cGMP were still 196 % 
lower than PPARγ expression measured in WT cells treated equally (Figure 
10a). 
 
Figure 10: Loss of sGC influences adipogenic program. 
Western blot analysis of brown WT and sGCb1-/- adipocytes differentiated in the absence or presence of 
200 µM 8-pCPT-cGMP. (a) Upper part representative Western blot of PPARγ, lower part densitometric 
quantification normalized to Tubulin. (b) Upper part representative Western blot of aP2, lower part 
densitometric quantification normalized to Tubulin; n>4 independent cell cultures. All data are 
represented as mean ± SEM and statistical testing was performed using Student t-test *p<0.05; 
***p<0.005.  
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Similar results were observed for the adipogenic marker aP2. Treatment of 
WT cells with cGMP led to a 213.3 ± 57.3 % increase of the aP2 
expression compared to untreated WT cells (Figure 10b). The loss of sGCβ1 
in these cells led to a 54.1 % decrease in aP2 protein compared to 
untreated WT cells (Figure 10b). sGCβ1-/- cells treated with cGMP increased 
aP2 expression to 163.7 ± 43.45 % in comparison to untreated WT cells 
(Figure 10b). In sGCβ1-/- cells treated with cGMP aP2 expression was 
3.6 fold increased in comparison to untreated sGCβ1-/- cells (Figure 10b). 
However, also aP2 expression levels in sGCβ1-/- cells remained reduced 
compared to WT cells when equally treated with cGMP. 
The protein level of UCP1 in WT cells treated with cGMP was significantly 
increased to 216.8 ± 31.3 % compared to untreated WT cells (Figure 11a). 
In contrast, sGCβ1-/- cells expressed 45.4 % less UCP1 than untreated WT 
cells (Figure 11a). Chronic treatment of sGCβ1-/- cells with cGMP increased 
the UCP1 protein level to 182.8 ± 25.8% compared to untreated WT cells 
(Figure 11a). In comparison to untreated sGCβ1-/- cells, UCP1 expression in 
sGCβ1-/- cells treated with cGMP was 3.4 fold increased (Figure 11a). 
Figure 11: Loss of sGC influences thermogenic program. 
Western blot analysis of brown WT and sGCb1-/- adipocytes differentiated in absence or presence of 
200 µM 8-pCPT cGMP. (a) Upper part representative Western blot of UCP1, lower part densitometric 
quantification normalized to Tubulin. (b) Upper part representative Western blot of Cytc lower part 
densitometric quantification normalized to Tubulin; n>4 independent cell cultures. All data are 
represented as mean ± SEM and statistical testing was performed using Student t-test *p<0.05; 
**p<0.01; ***p<0.005.  
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A similar expression pattern was detectable for Cytc. In comparison to 
untreated WT cells, the protein level was 219.5 ± 21.2 % increased after 
chronic cGMP treatment (Figure 11b). In contrast to untreated WT cells, 
the Cytc protein expression was significantly downregulated by 39.4 % in 
untreated sGCβ1-/- cells (Figure 11b). sGCβ1-/- cells treated with cGMP 
increased the expression of Cytc 1.7 fold compared to untreated sGCβ1-/- 
cells, which represents the basal expression level of Cytc in WT cells, thus 
cGMP treatment rescued protein levels of Cytc in sGCβ1-/- cells (Figure 
11b). 
 
 sGC deletion impairs mitochondrial biogenesis and lipolysis  
The finding that sGCβ1-/- cells and mice exhibited a diminished expression 
of UCP1, a protein located in the mitochondrial membrane, led to the 
analysis of mitochondrial biogenesis and BA function. Therefore, sGCβ1-/- 
and WT cells were differentiated in the presence or absence of cGMP and 
subsequently, expression of PGC-1a, a marker for mitochondrial 
biogenesis and the amount of mtDNA was determined. 
The mRNA expression of PGC-1a was significantly increased in WT cells 
treated with cGMP (1.8 ± 0.4 fold) compared to untreated WT cells (Figure 
12a). In contrast, untreated sGCβ1-/- cells expressed 65 % less PGC-1a in 
comparison to untreated WT cells (Figure 12a). sGCβ1-/- cells treated with 
cGMP showed similar PGC-1a expression as untreated WT cells (1.0 ± 0.4 
fold). In comparison to untreated sGCβ1-/- cells, sGCβ1-/- cells treated with 
cGMP significantly increased (2.8 fold) the expression of PGC-1a (Figure 
12a). Hence, cGMP rescued the reduction of PGC-1a levels in untreated 
sGCβ1-/- cells to the level detected in untreated WT cells (Figure 12a).  
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The mtDNA in sGCβ1-/- cells and WT was investigated in mature BAs. 
Therefore, genomic DNA was isolated and analyzed regarding the 
mitochondrial marker NADH dehydrogenase (Nd1), cytochrome b (Cytb) 
and cytochrome c oxidase subunit 1 (Co1). The expression of all three 
markers (Nd1, Cytb and Co1) was reduced by 47 %, 48 % and 28 %, 
respectively, compared to untreated WT cells (Figure 12b).  
To investigate the functional activity of BAs, the glycerol release was 
measured in mature WT and sGCβ1-/- BAs. By adding the initiator of 
lipolysis, NE, lipolytic activity of BAs was investigated. This treatment 
reveals further stimulation of lipolysis as under basal conditions. The 
lipolytic activity was investigated in untreated (basal) and acute NE-
stimulated mature BAs from sGCβ1-/- and WT cells. WT cells treated with 
NE acutely increased glycerol release 3.1 ± 0.4 fold compared to untreated 
WT cells (Figure 12c). In contrast to untreated WT cells, the lipolytic 
activity in untreated sGCβ1-/- cells was reduced by 46 %. Acute NE 
stimulation of sGCβ1-/- cells increased glycerol release 1.5 ± 0.3 fold 
compared to untreated WT cells (Figure 12c). sGCβ1-/- cells treated with NE 
significantly increased the lipolytic activity 2.9 fold compared to untreated 
sGCβ1-/- cells (Figure 12c). However, the glycerol release was still 
significantly lower in sGCβ1-/- cells treated with NE compared to WT cells 
treated with NE. These results show that sGCβ1 is important for the 
mitochondrial biogenesis and lipolytic activity of BAs. 
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Figure 12: sGC deficiency leads to reduced mitochondrial biogenesis and BAs function. 
(a) Gene expression levels of PGC-1α in brown WT and sGCb1-/- adipocytes differentiated in absence or 
presence of 200 µM 8-pCPT-cGMP; n=7-8 independent cell cultures. (b) Abundance of mitochondrial 
DNA markers NADH dehydrogenase (Nd1); cytochrome b (Cytb) and cytochrome c oxidase subunit 1 
(Co1) normalized to the chromosomal DNA encoded gene H19, n=3-5 independent cell cultures. (c) 
Lipolytic activity of WT and sGCb1-/- adipocytes in the absence or presence of NE. All data are 
represented as mean ± SEM and statistical testing was performed using Student t-test *p<0.05; 
**p<0.01; ***p<0.005.   
c 
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 Pharmacological stimulation of sGC enhances BA function  
 Stimulation of sGC influences cGMP production and lipid 
accumulation 
To address the question whether sGC might be a potential target to 
enhance BA differentiation, BAs were treated throughout differentiation 
with the sGC stimulator BAY 41-8543 in a concentration of 3 µM. As 
positive controls 200 µM cGMP and 50 µM DETA/NO as NO-Donor were 
used.  
In a first approach cGMP concentration was measured in WT cells as 
described in 2.4.5. Untreated BAs released 3.2 ± 1.1 fmol cGMP/ µg 
protein (Figure 13a). After 15 min incubation with the NO-donor DETA/NO 
the cGMP level was significantly increased by 3.7 fold in comparison to 
untreated control cells (Figure 13a). Stimulation of sGC with BAY 41-8543 
increased cGMP production 5.2 fold compared to untreated control cells 
(Figure 13a). A co-treatment of BAY 41-8543 and DETA/NO had a 
synergistic effect and led to a 14.4 fold increase of cGMP production in 
comparison to untreated control cells (Figure 13a). 
In addition to its effect on cGMP production, the effect of BAY 41-8543 on 
lipid uptake was investigated. Therefore, lipid storage in BAs was 
visualized by Oil RedO (Figure 13b). Again, chronic cGMP treatment led to 
an enhanced lipid accumulation in BAs (Figure 13b). The NO-Donor 
DETA/NO increased the amount of lipid droplets compared to control cells 
(b). The pharmacological stimulation of sGC also led to an increased lipid 
accumulation when cells were chronically treated with BAY 41-8543 
(Figure 13b).  
In order to quantify the Oil RedO staining, TG assay was performed. In 
comparison to control cells, cGMP treated cells significantly incorporated 
3.2 ± 0.9 fold more TG (Figure 13c). The TG content was 2.4 ± 0.8 fold 
increased in BAs treated with the NO-Donor DETA/NO compared to 
untreated control cells (Figure 13c). The highest increase in TG content 
was measured in BAs treated with BAY 41-8543 in comparison to control 
cells (Figure 13c). These results indicate that BAY 41-8543 increased cGMP 
concentration and led to a strong increase in TG content in BAs.  
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Figure 13: Stimulation of sGC influences cGMP production and lipid accumulation. 
(a) Basal DETA/NO and BAY 41-8543 stimulated cGMP content of brown adipocytes n=5 independent 
cell cultures. (b) Representative Oil RedO staining of brown adipocytes differentiated in the presence of 
200 µM 8-pCPT-cGMP, 50 µM DETA/NO and 3 µM BAY 41-8543. (c) Intracellular triglyceride content in 
brown adipocytes differentiated in the presence of 200 µM 8-pCPT-cGMP, 50 µM DETA/NO and 3 µM 
BAY 41-8543; n=5 independent cell cultures. All data are represented as mean ± SEM and statistical 
testing was performed using Student t-test *p<0.05.  
 
 sGC stimulator BAY 41-8543 enhances thermogenic and adipogenic 
program in BAs 
Based on the finding that BAY 41-8543 enhanced cGMP level and TG 
content of BAs, the effect of BAY 41-8543 on the adipogenic and 
thermogenic programs in BAs was analyzed in more detail. For this reason, 
the cells were chronically incubated with BAY 41-8543 throughout 
differentiation. Again, PPARγ, aP2 as well as UCP1 and Cytc were used as 
markers for the adipogenic and thermogenic program, respectively.  
In BAs treated with cGMP, PPARg protein levels were increased to 185.0 ± 
11.2 % in comparison to control cells (Figure 14a). The NO-Donor 
DETA/NO enhanced the expression to 141.8 ± 16.7 % compared to 
untreated control cells (Figure 14a). In comparison to untreated control 
cells, BAs treated with the sGC stimulator BAY 41-8543 significantly 
increased PPARg expression by 75.5 ± 25.3 % (Figure 14a). 
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The other investigated adipogenic marker aP2 showed a similar expression 
pattern as PPARg. Incubation with cGMP increased the protein level of aP2 
to 342.5 ± 123.7 % compared to control cells (Figure 14b). The NO-Donor 
DETA/NO increased the protein level to 288.3 ± 78.9 % (Figure 14b). BAY 
41-8543 had the strongest significant effect on the expression of aP2, the 
expression was increased to 425.0 ± 178.9 % compared to untreated 
control cells (Figure 14b). These results support the previous findings that 
stimulation of sGC is a strong enhancer of BA differentiation by increasing 
the adipogenic program. 
Figure 14: Chronic stimulation of sGC increases adipogenic program. 
Western blot analysis of brown adipocytes differentiated in the presence of 200 µM 8-pCPT-cGMP, 
50 µM DETA/NO and 3 µM BAY 41-8543. (a) Upper part representative Western blot of PPARγ, lower 
part densitometric quantification normalized to Tubulin. (b) Upper part representative Western blot of 
aP2, lower part densitometric quantification normalized to Tubulin; n>4 independent cell cultures. All 
data are represented as mean ± SEM and statistical testing was performed using Student t-test 
*p<0.05; ***p<0.005.  
 
UCP1 protein levels revealed that the chronic treatment with cGMP led to a 
significant increase in UCP1 expression compared to control cells (Figure 
15a). The NO-Donor increased the UCP1 protein level by 12.1 ± 34.9 % in 
comparison to control cells (Figure 15a). The strongest increase in UCP1 
protein level, 225.1 ± 28.2 %, was measured when cells were chronically 
treated with BAY 41-8543 compared to untreated control cells (Figure 
15a).  
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Chronic treatment with cGMP significantly increased the Cytc expression to 
116 ± 24.6 % in comparison to control cells (Figure 15b). In comparison 
to control cells, DETA/NO enhanced the protein expression by 
23.4 ± 26.5 % (Figure 15b). In line with the strongest increase in UCP1 
expression, BAY 41-8543 treatment also led to the strongest increase in 
Cytc expression (134.0 ± 25.6 %) compared to control cells (Figure 15b). 
In summary, pharmacological stimulation of the sGC resulted in a 
significant increase in differentiation which was based on an upregulation 
of the adipogenic and thermogenic program. 
Figure 15: Chronic stimulation of sGC increases thermogenic program. 
Western blot analysis of brown adipocytes differentiated in presence of 200 µM 8-pCPT-cGMP, 50 µM 
DETA/NO and 3 µM BAY 41-8543. (a) upper part representative Western blot of UCP1, lower part 
densitometric quantification normalized to Tubulin (b) upper part representative Western blot of Cytc, 
lower part densitometric quantification normalized to Tubulin; n>4 independent cell cultures. All data 
are represented as mean ± SEM and statistical testing was performed using Student t-test, *p<0.05; 
***p<0.005.  
 
For an enhanced BAT function, it is not only important that the adipogenic 
and thermogenic program are elevated, moreover, functionally active BAs 
are necessary. An indicator of BA activity is lipolytic activity. The basal 
lipolytic activity was measured in BAs treated with either cGMP, DETA/NO 
or BAY 41-8543 throughout differentiation.  
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Cells acutely treated with NE released 2.1 ± 0.6 fold more glycerol than 
unstimulated control cells (Figure 16). Chronic treatment with cGMP 
throughout differentiation increased basal lipolytic activity 1.9 ± 0.4 fold in 
comparison to untreated control cells (Figure 16). Chronic treatment with 
cGMP and a 2 h stimulation with NE increased the glycerol release 
5.5 ± 1.5 fold compared to untreated control cells (Figure 16). The NO-
Donor DETA/NO enhanced basal lipolytic activity 2.1 ± 0.34 fold compared 
to control cells (Figure 16). The treatment of BAs with DETA/NO and acute 
treatment with NE caused a significantly additional increase in glycerol 
release 5.8 ± 1.8 fold compared to untreated cells (Figure 16). The 
pharmacological stimulation of sGC with BAY 41-8543 increased basal 
lipolytic activity by 1.6 ± 0.2 fold in comparison to untreated control cells 
(Figure 16). An acute treatment with NE significantly enhanced the 
glycerol release in BAY 41-8543 treated BAs 3.9 ± 1.0 fold in comparison 
to untreated control cells (Figure 16). In summary, chronic treatment with 
BAY 41-8543 increases basal lipolytic activity, comparable to acute NE-
treated cells. Moreover, not only the basal lipolytic activity is increased, 
additionally BAs chronically treated with BAY 41-8543 and acutely 
stimulated with NE exhibit enhanced lipolytic activity and this argues for 
an enhanced BA function. 
 
Figure 16: Pharmacological stimulation of sGC leads to an enhanced BAT function. 
Measurement of glycerol release under basal and NE-stimulated conditions in brown adipocytes 
differentiated in presence of 200 µM 8-pCPT-cGMP, 50 µM DETA/NO and 3 µM BAY 41-8543, n>4 
independent cell cultures. All data are represented as mean ± SEM and statistical testing was 
performed using Student t-test *p<0.05. 
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 sGC stimulation protects against diet-induced obesity 
 Pharmacological stimulation of sGC protects against weight gain 
After identifying promising results in vitro, the effect of sGC stimulation on 
whole body metabolism was analyzed in more detail in vivo. Therefore, WT 
mice were fed a control diet (CD), high fat diet (HFD) or high fat diet 
supplemented with the sGC stimulator BAY 41-8543 (HFD+BAY41) for 12 
weeks and changes in body weight were recorded weekly (Figure 5). 
During the recorded time, mice fed the HFD and HFD+BAY41 gained more 
weight compared to mice fed the CD and at the 12 weeks’ time point, mice 
fed a HFD gained 42.8 % more weight than mice fed the CD (Figure 17a). 
Addition of BAY41 to the HFD significantly decreased body weight gain 
resulting in 14.6 % less body weight at the 12 weeks’ time point in 
comparison to mice fed only a HFD (Figure 17a).  
It is well known that body weight changes are accompanied with changes 
in body composition(Kushner et al., 1990). Therefore, body composition 
was analyzed using NMR. Mice fed a HFD for 12 weeks had 88.0 % more 
fat mass than mice receiving CD (Figure 17b). In contrast, HFD+BAY41 
mice exhibited only 59.0 % more fat mass compared to mice on a CD 
(Figure 17b). The weight of the water content was not significantly 
changed between all three groups (Figure 17b). The lean mass of mice fed 
a CD or a HFD was not changed, whereas the lean mass of HFD+BAY41 
mice increased by 7.0 % in comparison to mice on CD (Figure 17b). In 
summary, pharmacological stimulation of sGC in combination with the HFD 
reduced gain in fat mass compared to mice on a HFD.   
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Figure 17: Pharmacological stimulation of sGC protects against weight gain. 
(a;b) Effects of a control diet (CD), a high fat diet (HFD) with or without BAY 41-8543 (HFD+BAY41) 
on body weight (a) and body composition (b). (a) Significant *HFD versus CD; #BAY versus CD; §BAY 
versus HFD and for (b) *fat; ‘lean; + free water(c). Tissue weights of inguinal WAT (WATi) and 
gonadal WAT (WATg), interscapular brown adipose tissue with WAT (BAT), liver and muscle after 
treatment with or without BAY. All data are represented as mean ± SEM and statistical testing was 
performed for a two-way of variance (ANOVA) and b and c Student t-test was used, **p<0.01; ***p< 
0.005. 
 
The detected changes in body composition let to the hypothesis that also 
tissue weights were altered upon HFD. Therefore, after 12 weeks of 
feeding a CD, a HFD or a HFD+BAY41, the mice were sacrificed and the 
tissue weights were analyzed. The weight of WATi of mice fed the HFD was 
124 % increased in comparison to mice fed the CD (Figure 17c). In 
contrast, HFD+BAY41 resulted only in an increase of 20 % in WATi weight 
compared to CD fed mice (Figure 17c). Mice that had been fed with a 
HFD+BAY41 exhibited a reduction in the weight of WATg by 55 % and BAT 
by 38.0 % when compared to mice fed only a HFD (Figure 17c). 
The liver weight of mice on a HFD was 7.3 % lighter than the liver weight 
of mice on a CD for 12 weeks, whereas feeding the HFD+BAY41 did not 
result in significant changes (Figure 17c). The tissue weights of the muscle 
remained unaffected (Figure 17c). These results are contradictory to the 
obtained body composition as mice fed a HFD+ BAY41 had a higher lean 
mass. Nonetheless, these in vivo results reveal that mice treated with the 
sGC stimulator plus a HFD possess lighter adipose tissues than mice only 
fed a HFD.  
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 Enhanced metabolic effects after sGC stimulation  
Next, metabolic cages were used to record indirect calorimetry, which 
means VO2 consumption over 24 h, energy intake and the locomotion 
activity over the night and day period. As before, mice were fed for 12 
weeks with CD, HFD or HFD+ BAY41-8543 and the measurements were 
taken during the last week of the study in metabolic cages.  
Indirect calorimetry showed no significant changes between CD and mice 
on HFD during the day period (0600-1800) (Figure 18a, b). Interestingly, 
HFD+BAY41 mice had a significant increase in O2 consumption compared 
to mice fed a CD or HFD during the day cycles (Figure 18a, b). The indirect 
calorimetric measurement by oxygen consumption has one limitation as it 
does not consider the body weight, which was shown to be significantly 
altered after feeding the mice the HFD and HFD+BAY41 when compared to 
mice on CD (Figure 17a). Therefore, mean energy expenditure was 
correlated with body weight and indeed, this correlation confirmed that 
HFD+BAY41 mice had the highest O2 consumption (Figure 18c).  
Measurement of the energy intake showed that mice fed HFD consumed 
32.7 % less energy than mice on the CD (Figure 18d). Interestingly, 
HFD+BAY41 mice ingested 25.0 % more energy than mice fed CD (Figure 
18d). To rule out that the different diets and energy intake levels had an 
influence on the motility, the locomotion activity was analyzed. 
Surprisingly, there was no significant difference between all three groups 
(Figure 18e). These results demonstrate that mice fed a HFD+BAY41 have 
a higher energy expenditure, an increased food intake and a comparable 
locomotor activity compared to mice fed only a HFD, but unexpectedly 
their body weight remained significantly lower.  
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Figure 18: Metabolic measurements after 12 weeks feeding with CD, HFD and HFD+sGC 
stimulator. 
(a;b) Oxygen consumption (VO2) (a) and mean oxygen consumption during day and night (b) after 
feeding 12 weeks a control diet (CD), high fat diet (HFD) or high fat diet with sGC stimulator BAY 41-
8543 (HFD+BAY41).(c) Mean energy expenditure in relation to the body weight. (d) Energy intake of 
mice within 24 h. (e) Motility during light and dark cycles within 24h of mice fed a CD, HFD or 
HFD+BAY 41-8543 All data are represented as mean ± SEM and statistical testing was performed 
using Student t-test, * p< 0.05; ***p<0.005. 
 
 sGC stimulator BAY 41-8543 enhances glucose clearance.  
A long-term high fat diet could result in the development of diabetic 
phenotypes and therefore, a glucose tolerance test (GTT) was performed 
in the last week of the study. The mice were weighed and then their basal 
glucose level was measured. After intraperitoneal injection of a glucose 
solution, blood glucose level was measured every 30 min. The basal 
glucose level was significantly increased in mice fed a HFD or HFD+BAY41 
compared to CD fed mice (Figure 19a). 30 min after the glucose injection 
there was no significant difference in glucose level of mice fed a HFD or a 
HFD+BAY41 (HFD:410.3 ± 19.8 mg/dl; HFD+BAY41:414.0 ± 14.5 mg/dl) 
(Figure 19a).  
A significant change between mice fed a HFD or HFD+BAY41 could be 
observed after one hour post glucose injection, when mice treated with the 
sGC stimulator had cleared already 25.0 % more glucose than mice fed 
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HFD only (Figure 19a). Interestingly, two hours after glucose injection the 
difference in the glucose level between HFD+BAY41 mice and mice fed a 
CD was only 14 %, whereas the glucose level in mice fed the HFD was still 
significantly higher (Figure 19a). 
Based on the finding that mice fed the sGC stimulator had a better glucose 
clearance, the insulin plasma levels of these mice were analyzed. The 
insulin plasma level of mice fed a HFD was increased by 729.2 % 
compared to mice on a CD (Figure 19b). Interestingly, HFD+BAY41 mice 
had a 50.0 % reduction in plasma insulin in comparison to mice fed only 
HFD (Figure 19b). These results demonstrate that mice treated with the 
pharmacological compound did not develop a diabetic phenotype.  
 
Figure 19: sGC stimulator BAY 41-8543 enhances glucose clearance after 12 weeks on a 
HFD. 
(a) Glucose tolerance test after 12 weeks on a control diet (CD); a high fat diet (HFD) with or without 
BAY 41-8543 (HFD+BAY41); *HFD versus CD; # BAY versus CD, § BAY versus HFD. (b) Insulin plasma 
level at the end of the study. All data are represented as mean ± SEM and statistical testing was 
performed using Student t-test, *** p< 0.005.  
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  Metabolic changes in brown adipose tissue after sGC stimulation 
 Acute NE stimulation increases BAT activity in mice treated with sGC 
stimulator 
To investigate whether the BAT activity is increased in mice treated with 
HFD+BAY41, NE-induced thermogenesis was measured. Therefore, the 
resting metabolic rate (RMR) was analyzed and then NE (as mimic for cold 
stimulation) was subcutaneously injected. Afterwards, O2 consumption was 
recorded for 2 h.  
Interestingly, the basal O2 consumption was significantly increased in 
HFD+BAY41 mice compared to mice fed a HFD (Figure 20a). After NE 
injection HFD+BAY41 mice consumed significantly more O2 than mice only 
fed a CD or HFD (Figure 20a). Furthermore, after calculating the area 
under the curve (AUC) of the mean oxygen consumption after NE 
injection, HFD+BAY41 mice consumed significantly more O2 than mice fed 
a CD or a HFD, whereas there were no significant changes between mice 
fed a CD or a HFD (Figure 20b). These results indicate that mice fed the 
sGC stimulator have an enhanced BAT activity and a higher O2 
consumption after acute NE stimulation. 
  
Figure 20: sGC stimulator BAY 41-8543 enhances BAT activity after acute cold stimulation. 
(a) Norepinephrine (NE) induced thermogenesis in BAY41-8543 treated mice. Mice were fed a control 
diet (CD); a high fat diet (HFD) with or without BAY 41-8543 (HFD+BAY41) for 12 weeks. The resting 
metabolic rate (RMR) was analyzed at thermoneutrality (30°C). NE was used to induce maximal 
thermogenesis *BAY+HFD versus CD; # HFD versus CD, § BAY versus HFD. (b) Area under the curve 
(AUC) of mean oxygen consumption after NE injection; n=3 mice per group. All data are represented 
as mean ± SEM and statistical testing was performed using Student t-test, *p<0.05 ** p< 0.01.  
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 Treatment with the sGC stimulator BAY 41-8543 increases lipid 
uptake in BAT 
The sGC stimulator highly activates BAT after acute NE stimulation. To 
characterize BAT function in mice fed a CD, HFD or a HFD+BAY41 for 12 
weeks in more detail, the following assays were performed: uptake of 
radioactive-labelled lipids, relative mRNA abundance of proteins involved 
in lipid uptake and thermogenic program as well as mitochondrial 
biogenesis. The lipid uptake assay revealed that mice fed a HFD contained 
44.0 % less radioactive-labelled lipids than mice on a CD (a). On the 
contrary, HFD+BAY41 mice incorporated 50.0 % more radioactive-labelled 
lipids compared to mice on a HFD (Figure 21a). 
Next, the expression levels of CD36 and LPL, two proteins involved in lipid 
uptake, were analyzed. The expression of CD36 in mice fed a HFD was 
1.3 ± 0.4 fold, whereas LPL expression increased 3.5 ± 1.3 fold, both 
related to mice fed a CD (Figure 21b). HFD+BAY41 mice, however, had a 
more dramatic and thus significant increase in mRNA expression of both 
proteins, CD36 increased 1.9 ± 0.5 fold and LPL 17.4 ± 6.3 fold, 
respectively, compared to mice fed a CD (Figure 21b).  
The thermogenic marker Ucp1 was 1.7 ± 0.6 fold and Adrb3 was 3.5 ± 1.2 
fold increased in mice fed a HFD compared to CD fed mice (b). Ucp1 and 
Adrb3 expression were increased 3.1 ± 0.7 fold and 4.8 ± 1.7 fold, 
respectively, in HFD+BAY41 mice compared to CD fed mice (Figure 21b).  
The markers for mitochondrial biogenesis like Pgc-1α and Nrf1 were 
increased 1.2 ± 0.4 fold and 1.6 ± 0.2 fold, respectively, in mice fed a 
HFD in comparison to mice fed a CD (Figure 21b). In HFD+BAY41 mice 
Pgc-1α and Nrf1 expression were significantly increased by 1.9 ± 0.5 fold 
and 4.3 ± 0.9 fold, respectively, compared to CD fed mice (Figure 21b).   
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As all these marker proteins are differentially expressed in mice fed a HFD 
and treated with the sGC stimulator, also expression levels of proteins 
involved in glucose uptake were analyzed. Gene expression of SLC2A1 was 
4.41 ± 1.28 fold increased whereas SLC2A4 was only 2.8 ± 1.2 fold 
increased in mice fed a HFD compared to mice on a CD (Figure 21c). In 
contrast, HFD+BAY41 mice expressed 11.9 ± 3.1 fold more SLC2A1 and 
4.1 ± 2.0 fold more SLC2A4 than mice fed a CD (Figure 21c).  
Taken together, these results show that the sGC stimulator enhanced the 
lipid uptake in BAT and increased the expression of functional markers for 
BAT activity.  
 
Figure 21: sGC stimulator BAY 41-8543 increases lipid uptake in BAT. 
(a) Lipid uptake (14C-Triolein) into BAT in mice fed for 12 weeks a control diet (CD), a high fat diet 
(HFD) with or without BAY 41-8543 (HFD+BAY41). (b) Expression level of marker for lipid uptake 
(CD36 and LPL), thermogenesis (Ucp1 and Adrb3) and mitochondrial biogenesis (Pgc-1α and Nrf1). (c) 
Relative mRNA expression of glucose uptake markers (SLC2A1 and SLC2A4). All data are represented 
as mean ± SEM and statistical testing was performed using Student t-test, *p<0.05, *** p< 0.005.  
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 Mice treated with the sGC stimulator BAY 41-8543 exhibit improved 
BAT function  
The previous results highlight that mice fed the sGC stimulator during HFD 
gained less weight and incorporated more lipids, the underlying 
mechanism for the improved BAT activity, however, remained unclear. 
Hence, histological sections of BAT of mice fed a CD, HFD or HFD with BAY 
41-8543 for 12 weeks were analyzed and the expression levels of UCP1 as 
well as the mitochondrial content and Vegf mRNA expression were 
determined.  
The histological section revealed an increased lipid content in mice fed a 
HFD for 12 weeks. In contrast, HFD+BAY41 mice stored less lipids in BAT 
(Figure 22a). The UCP1 expression showed no obvious difference between 
the three groups (Figure 22a). For quantification, the protein levels of 
UCP1 were analyzed. Mice fed a HFD did not exhibit a significant increase 
in expression compared to mice fed a CD (Figure 22b). Contrariwise, 
HFD+BAY41 mice expressed significantly, 78.0 ± 42.8 %, more UCP1 than 
mice fed a CD (Figure 22b).  
Moreover, DNA marker for mitochondrial content were measured by qRT-
PCR. The expression levels of Cytb and Co1 in BAT were not significantly 
increased in mice fed a HFD, the expression of Cytb was 1.7 ± 0.6 fold and 
Co1 was 1.2 ± 0.3 fold increased, respectively (Figure 22c and d). 
HFD+BAY41 mice, however, expressed 3.08 ± 0.83 fold more Cytb and 
4.1 ± 1.5 fold more Co1 compared to CD mice (Figure 22c and d). 
To investigate whether the mtDNA content is also affected in WATi, which 
would be a hint for browning of WATi, Cytb and Co1 content was measured 
in WATi. The expression level of Cytb and Co1 in WATi were not 
significantly altered in mice fed a HFD, the expression of Cytb was 
2.0 ± 1.5 fold and Co1 was 1.7 ± 0.3 fold increased (Figure 22c and d). 
On the contrary, HFD+BAY41 mice exhibited an increased expression of 
Cytb (1.5 ± 0.8 fold) and Co1 (1.5 ± 0.4 fold) compared to CD fed mice 
(Figure 22c and d).  
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The Vegf expression in mice fed a HFD was 1.3 ± 0.3 fold increased in 
comparison to CD mice (Figure 22e). Furthermore, in HFD+BAY41 mice 
the expression of Vegf was significantly (2.3 ± 0.1 fold) increased 
compared to mice fed a CD (Figure 22e). These results demonstrate that 
treatment with the sGC stimulator increased mitochondrial content in BAT 
and WATi as well as vascularization of BAT.  
 
Figure 22: sGC stimulator BAY 41-8543 enhances BAT function. 
Analysis of brown adipose tissue from mice fed a control diet (CD), a high fat diet (HFD) with or 
without BAY 41-8543 (HFD+BAY41) for 12 weeks. (a) Representative histology of BAT stained against 
UCP1 and hematoxylin, scale bar 100 µm (b) UCP1 protein expression in BAT, representative Western 
blot (left) and densitometric quantification normalized to β-Actin (right); n=8. (c and d) Mitochondrial 
DNA content in BAT and WATi. Abundance of mitochondrial DNA markers (c) cytochrome c oxidase 
subunit 1 (Co1) and (b) cytochrome b (Cytb) and normalized to the chromosomal DNA encoded gene 
H19, n=5-7. (e) Vegf expression in BAT; n=8. All data are represented as mean ± SEM and statistical 
testing was performed using Student t-test, *p<0.05 ** p< 0.01.   
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 Metabolic changes in white adipose tissue after sGC stimulation 
 Stimulation of sGC leads to an improved lipid uptake in WATi and 
reduces adipocytes diameter 
It is common knowledge that redundant calories are stored in white 
adipose tissue, thus the existing hypothesis is that mice fed a HFD store 
more lipids in the adipose tissue (Hausman et al., 1997). To verify this in 
our settings, lipid uptake and TG content as well as adipocyte sizes were 
measured in mice fed a CD, HFD or HFD+BAY41 for 12 weeks.  
The uptake of radioactive-labelled lipids in WATi of mice fed a HFD was 
1.4 fold higher compared to mice fed a CD (Figure 23a). Interestingly, 
HFD+BAY41 mice incorporated 1.8 fold more radioactive-labelled lipids 
into WATi than mice fed a CD (Figure 23a).  
The analyzed TG content demonstrated that mice on a HFD store 
73.6 ± 46.7 % more lipids than mice fed a CD (Figure 23b). The TG 
content in WATi of HFD+BAY41 mice was not significantly increased in 
comparison to mice on a CD, leading only to an increase in TG content of 
50.0 ± 32.5 % (Figure 23b). In summary, feeding mice a HFD 
supplemented with the sGC stimulator resulted in an enhanced lipid uptake 
in WATi but did not alter the lipid storage.  
 
Figure 23: sGC stimulator BAY 41-8543 influences lipid uptake in WATi. 
(a) Lipid uptake (14C-Triolein) into WATi in mice fed 12 weeks a control diet (CD), a high fat diet (HFD) 
with or without BAY 41-8543 (HFD+BAY41). (b) TG content of WATi in mice on a diet for 12 weeks. All 
data are represented as mean ± SEM and statistical testing was performed using Student t-test, 
*p<0.05.  
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These results could support the hypothesis that in HFD fed mice redundant 
calories were stored in adipose tissue. The histological analyses of WATi of 
mice fed a HFD indeed revealed bigger lipid droplets than mice fed a CD. 
In contrast, WATi of HFD+BAY41 mice possessed lipid droplets that were 
greatly reduced in size when compared to mice fed a HFD (Figure 24a).  
To quantify these results, the adipocytes diameter was measured in each 
group. Mice fed a HFD exhibited a significant, 1.7 fold bigger adipocytes 
diameter than mice fed a CD (Figure 24b). In contrast, the adipocytes 
diameter of HFD+BAY41 mice was not significantly altered compared to 
mice fed a CD (Figure 24b). These results demonstrate that the sGC 
stimulator protected mice against excess gain of adipose tissue mass. 
 
Figure 24: sGC stimulation leads to decreased adipocyte sizes. 
(a) Representative images of WATi section stained with hematoxylin and eosin. (b) Adipocytes 
diameter of WATi adipocytes. All data are represented as mean ± SEM and statistical testing was 
performed using Student t-test, ***p<0.005.  
 
 Browning effect in WATi after sGC stimulation with BAY 41-8543 
Earlier results from in vitro studies showed that the treatment with the 
sGC stimulator enhanced the function of the BAs. It has been shown by 
Mitschke et al. that activation of the cGMP/PKGI pathway also induces a 
browning effect in WAs (Mitschke et al., 2013). For this reason the ability 
of the sGC stimulator to induce browning was analyzed.  
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Therefore, WATi was stained against UCP1 and with haematoxylin to 
visualize the cell nucleus. Treatment with the HFD for 12 weeks reduced 
UCP1 expression in WATi compared to mice fed a CD (Figure 25). 
Surprisingly, HFD+BAY41 mice exhibited the highest UCP1 expression 
compared to CD and HFD fed mice. These results emphasize that the sGC 
stimulator induces browning in WATi.  
 
Figure 25: sGC stimulator enhances browning effect of WATi. 
Analysis of browning capacity in WATi of mice fed 12 weeks a control diet (CD), a high fat diet (HFD) 
with or without BAY 41-8543 (HFD+BAY41). Representative images of WATi section stained with 
hematoxylin and UCP1, scale bar 100 µM.  
 
 sGC stimulation influences muscle metabolism 
 Increased lipid uptake into muscles after treatment with 
BAY 41-8543 
Mice that had been fed for long term with HFD+sGC stimulator exhibit 
enhanced BAT activity, increased browning of WATi, and a minor weight 
gain compared to mice fed a HFD. Additionally, muscle weight was not 
altered by the three different diets. The NMR results, however, revealed an 
increased lean mass. Consequently, the effect of sGC stimulator on muscle 
metabolism was further analyzed. Therefore, the lipid uptake in soleus 
muscle of mice fed a CD, HFD or HFD+BAY41- was measured. Additionally, 
in these mice the TG content was determined and gene analysis in calf 
muscle was performed.  
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The 14C-triolen uptake in muscle of mice fed a HFD was 2.6 fold increased 
in comparison to CD fed mice (Figure 26a). The highest amount of lipids 
was incorporated into the muscle of HFD+BAY41 mice leading to a 3.3 fold 
increase compared to CD fed mice (Figure 26a). 
The question whether the increased lipid uptake in the muscle results in an 
enhanced lipid storage remains unsolved. Hence, the TG content of the calf 
muscle was measured. The TG content of muscle from mice fed a HFD was 
increased by 78.0 ± 48.7 % compared to mice that had received a CD 
(Figure 26b). In contrast, HFD+BAY41 led only to a 35.0 ± 35.8 % 
increase in TG content compared to mice fed a CD (Figure 26b). Even 
through the TG content results were overall not significant, they suggest 
that mice fed with a HFD supplemented with BAY 41-8543 incorporated an 
enhanced quantity of lipids but they did not store them within the muscle.  
 
Figure 26: sGC stimulator enhances lipid uptake in muscle . 
(a) Lipid uptake (14C-Triolein) in muscle of mice fed a control diet (CD), a high fat diet (HFD) with or 
without BAY 41-8543 (HFD+BAY41) for 12 weeks; n= 6-8 per group. (b) TG content of muscle from 
mice fed a CD, HFD or BAY+HFD; n=8 per group. Gene expression marker of lipid uptake (Cd36, Lpl 
and SLC7A3), glucose uptake (Glut4), mitochondrial biogenesis (Pgc-1α and Nrf1), mitochondrial 
function (Ucp3 and Atp5g1) and fatty acid catabolism (Pparδ and Cpt1b), n=8 per group. All data are 
represented as mean ± SEM and statistical testing was performed using Student t-test, *p<0.05, 
**p<0.001, ***p<0.005.   
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Due to this finding, the question of how the lipids are further processed 
still remains. Therefore, the expression pattern of different marker 
proteins was analyzed to investigate whether the muscle metabolism was 
altered. As marker proteins involved in lipid uptake, the mRNA levels of 
Cd36, Lpl and Slc27A3 were determined. Feeding a HFD over 12 weeks 
significantly increased the expression of Cd36 (6.4 ± 2.6 fold) and Lpl 
(1.99 ± 0.35 fold) but did not alter the expression of Scl27a3 (1.0 ± 0.1 
fold) in comparison to CD fed mice (Figure 26c). Muscle of HFD+BAY41 
mice showed an enhanced expression of all lipid uptake markers: Cd36 
increased 4.1 ± 2.3 fold, Lpl 2.2 ± 0.7 fold and Scl27a3 2.2 ± 0.5 fold in 
comparison to CD fed mice (Figure 26c). The expression of glucose uptake 
markers in the muscle was not significantly altered in HFD+BAY41 or HFD 
fed mice compared to CD fed mice (Figure 26c). 
Marker for the mitochondrial biogenesis were not significantly increased in 
mice fed a HFD. The expression of Pgc-1α and Nrf1 was 1.6 ± 0.4 fold and 
1.0 ± 0.3 fold increased, respectively, compared to mice treated with CD 
(Figure 26c). In comparison to CD mice, the expression of Pgc-1α was 2.2 
± 0.4 fold and Nrf1 2.3 ± 0.3 fold increased in HFD+BAY41 fed mice, 
which represent significant changes in the expression levels. Analyzed 
expression markers for mitochondrial function are Ucp3 and Atp5g1. In 
mice fed a HFD for 12 weeks, expression of Ucp3 was not significantly 
increased, the levels of Atp5g1, however, were significantly increased 
(Figure 26c). Interestingly, expression of both marker was significantly 
enhanced in muscle of HFD+BAY41 mice compared to mice fed a CD 
(Figure 26c).  
Expression levels of markers for the fatty acid catabolism, namely Pparδ 
and Cpt1b, were augmented in muscle of mice fed a HFD in comparison to 
mice fed a CD. Pparδ was 1.5 ± 0.5 fold and Cpt1b was 1.7 ± 0.3 fold 
increased (Figure 26c). A similar expression pattern was observed in the 
muscle of HFD+BAY41 mice. The expression levels of both markers were 
significantly increased (Figure 26c). These results highlight that 
stimulation with the sGC stimulator resulted not only in an increased lipid 
uptake in the muscle, it furthermore also augmented the expression of 
several marker proteins involved in lipid metabolism in the muscle.   
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 Muscle fiber type switch in mice fed a HFD+BAY 41-8543  
In addition to analyzing the muscle metabolism, changes in muscle fibre 
types were explored as the sGC stimulator may not only improve the 
muscle metabolism but could also induce a muscle fiber switch. For this 
purpose, the calf muscle was analyzed for expression of myosin heavy 
chains (MHC) which are an indicator for the function and endurance. The 
expression of the myosin heavy chain I (MHCI) was increased in HFD fed 
mice in comparison to mice fed a CD (3.2 ± 1.4 fold) (Figure 27a). Also, 
mice fed HFD+BAY41 expressed higher levels of MHCI (2.5 ± 0.9 fold) 
compared to mice fed a CD, however only the HFD+BAY41 fed mice 
exhibited a significant increase in MHCI expression (Figure 27a). The gene 
expression of MHCIIa and MHCIIb was not significantly increased in mice 
fed a HFD in comparison to mice receiving the CD (Figure 27a). In 
contrast, an increased expression of MHCIIa by 2.1 ± 0.5 fold and MHCIIb 
by 1.8 ± 0.2 fold was detected in HFD+BAY41 mice compared to CD 
(Figure 27a). The expression of MHCIIx was not affected neither by HFD 
nor by HFD+BAY41 (Figure 27a).  
As a next step the genomic DNA from calf muscle was isolated and 
analyzed regarding the expression of the mitochondrial marker NADH 
dehydrogenase (Nd1); cytochrome b (Cytb) and cytochrome c oxidase 
subunit 1 (Co1) to investigate if the mitochondrial biogenesis was also 
affected upon addition of the sGC stimulator. No significant changes, 
however, could be observed for any of the analyzed marker proteins, 
neither in mice fed a HFD nor in mice fed a HFD+BAY41 compared to CD 
fed mice (Figure 27b). Taken together, these results demonstrate that 
treatment with the sGC stimulator altered the composition of the muscle 
fiber type but it had no significant impact on mitochondrial DNA 
expression. 
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Figure 27: sGC stimulator leads to a muscle fiber type switch. 
(a) Relative mRNA abundance of muscle fiber (myosin heavy chain I, IIa, IIb and IIx) of mice fed 12 
weeks a control diet (CD), a high fat diet (HFD) with or without BAY 41-8543 (HFD+BAY41); n= 7-8 
per group. (b) Abundance of mitochondrial DNA markers NADH dehydrogenase (Nd1); cytochrome b 
(Cytb) and cytochrome c oxidase subunit 1 (Co1) normalized to the chromosomal DNA encoded gene 
H19, n=8 per group. All data are represented as mean ± SEM and statistical testing was performed 
using Student t-test, *p<0.05. 
 BAY 41-8543 protects against liver steatosis  
Treatment with BAY 41-8543 accounts for an enhanced muscle 
metabolism, reduced body weight and diminished adipocytes size. 
Nevertheless, it remains ambiguous where the excess amount of lipids is 
stored as it is not deposited in the adipose tissue. Another tissue prone to 
store excess lipids is the liver, a condition resulting in liver steatosis.  
To investigate this, the lipid uptake in the liver and the TG content of the 
liver were measured. Measurements of lipid uptake in the liver revealed 
that mice on HFD incorporated significantly (1.7 fold) more lipids than 
mice fed a CD (Figure 28a). Interestingly, HFD+BAY41 mice incorporated 
even more lipids (2.2 fold) into the liver compared to mice on a CD (Figure 
28a). These results could strengthen the hypothesis that treatment with 
the sGC stimulator triggers a severe fatty liver in mice. To rule out the 
subsequent development of a fatty liver, TG assay was performed. Mice 
fed with a HFD for 12 weeks stored 83.0 % more TG in the liver than mice 
fed a CD (Figure 28b). In contrast, HFD+BAY41 mice had only a minor 
increase of 3 % in the TG content compared to mice on a CD (Figure 28b). 
The underlying mechanisms of exceeded lipid uptake in mice fed a 
HFD+BAY41, however, remained elusive. To gain more insights in liver 
function, expression of a marker for hepatic gluconeogenesis (Glucose6-
Phosphatase=Gcp6), of the oxidative stress detoxifying gene 
(catalase=Cat) and energy dissipation gene (uncoupling protein 2=Ucp2) 
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in the liver was analyzed. The gene expression of the marker for hepatic 
Gcp6 showed a 1.7 ± 0.5 fold increase in mice fed a HFD over 12 weeks 
(Figure 28c), whereas its expression level remained unaffected in mice fed 
a HFD+BAY41, both conditions compared to mice fed a CD (Figure 28c). 
The mRNA expression of Cat was 2.5 ± 0.1 fold enhanced in mice fed a 
HFD in comparison to CD fed mice (Figure 28c). Again, the expression of 
Cat was not significantly affected in HFD+BAY41 mice compared to mice 
fed a CD (Figure 28c). Finally, the expression of the energy dissipation 
marker Ucp2 remained independent of the different diets. Taken together, 
the sGC stimulator represents a potent drug against the development of a 
liver steatosis in mice, which is a comorbidity of obesity. 
 
Figure 28: sGC stimulator enhances liver metabolism.  
(a) Lipid uptake (14C-Triolein) in liver of mice fed 12 weeks a control diet (CD), a high fat diet (HFD) 
with or without BAY 41-8543 (HFD+BAY41); n= 6-8 per group (Study performed by Prof. Heeren’s 
lab.). (b) TG content of liver from mice fed a CD, HFD or BAY+HFD; n=8 per group. Gene expression 
marker of hepatic gluconeogenesis (Glucose6-Phosphatase=Gcp6), oxidative stress detoxifying genes 
(catalase=Cat) and energy dissipation (Ucp2) in liver, n=8 per group. All data are represented as 
mean ± SEM and statistical testing was performed using Student t-test, *p<0.05, **p<0.001, 
***p<0.005.   
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 Effects of sGC stimulator BAY 41-8543 on already established obesity 
In addition to the prevention study described above, another and more 
clinical relevant approach was undertaken, in which the effect of the sGC 
stimulator in mice with already established obesity was investigated. Not 
only the effect of sGC stimulation and a HFD was analyzed, also the 
consequences after a diet change and additional treatment with the sGC 
stimulator were investigated. Therefore, body weight, glucose tolerance 
test, metabolic measurements and tissue weights as well as plasma level 
of leptin, adiponectin and insulin were analyzed. 
 sGC stimulator BAY 41-8543 influences body weight. 
Mice were fed a HFD for 12 weeks and after this, the diet was changed for 
6 additional weeks. One group was fed a HFD (HFD-HFD) and the second 
group was fed a HFD+BAY 41-8543 (HFD-BAY+HFD). The third group was 
switched to CD (HFD-CD) and the fourth group was fed a CD plus the sGC 
stimulator BAY 41-8543 (HFD-BAY+CD). The fifth group was fed a CD from 
the beginning (CD). Before changing the diet, all mice on a HFD weighed 
39.9 ± 1.4 g, mice just receiving the CD weighed 27.7 ± 0.7 g (Figure 
29a). At the end of the study HFD-HFD mice weighed 47.9 ± 1.2 g (Figure 
29a). HFD-BAY+HFD mice weighed 13 % less than HFD-HFD mice (Figure 
29a). Interestingly, a diet switch reduced the body weight in HFD-CD to 
29.4 ± 0.7 g and HFD-BAY+CD mice exhibited a reduction in body weight 
by 8 % in comparison to HFD-CD fed mice at the end of the study (Figure 
29b). In contrast, mice fed a CD from the beginning of the study weighed 
29.1 ± 0.6 g after 18 weeks. These results demonstrate that BAY 41-8543 
can boost the reduction of the body weight also in combination with a CD.  
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Figure 29: Effects of sGC stimulator BAY 41-8543 on already established obesity. 
(a;b) Effects of weight gain after already established obesity. Therefore, mice were fed a HFD for 12 
weeks and then diet was changed, to (a) HFD (HFD-HFD) or HFD plus BAY 41-8543 (HFD-BAY+HFD) 
for additional six weeks, (b) or CD (HFD-CD) and CD plus BAY 41-8543 (HFD-BAY+CD) also for the six 
additional weeks, n=8 mice per group, #CD versus HFD-CD, + CD versus HFD-CD+BAY, *HFD-CD 
versus HFD-CD+BAY. All data are represented as mean ± SEM and statistical testing was performed 
using two-way analysis of variance (ANOVA). *,#,+p<0.05, **,##,++p<0.01, ###,+++p<0.005. 
 
 
 BAY 41-8543 increases energy expenditure and improves glucose 
clearance  
At the end of the study O2 consumption and glucose clearance were 
measured. HFD-BAY+HFD mice consumed significantly more O2 during day 
and night compared to HFD-HFD mice (Figure 30a). Surprisingly, the diet 
change to CD plus BAY 41-8543 for additional six weeks (HFD-BAY+CD) 
did not significantly enhance the O2 consumption compared to mice fed 
only a CD (Figure 30b).  
Figure 30: BAY 41-8543 increases energy expenditure after already established obesity. 
(a;b) Mean energy expenditure (VO2) during day and night cycle after established obesity. Therefore, 
mice were fed a HFD for 12 weeks and then diet was changed, to (a) HFD (HFD-HFD) or HFD plus BAY 
41-8543 (HFD-BAY+HFD) for additional six weeks, (b) or CD (HFD-CD) and CD plus BAY 41-8543 
(HFD-BAY+CD) also for six additional weeks, n=8 mice per group. All data are represented as mean ± 
SEM and statistical testing was performed using Student t-test, *,p<0.05, ***p<0.005. 
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Furthermore, GTT was performed to validate if the sGC stimulator also 
improves the glucose clearance after already established obesity. The 
basal glucose level was not significantly different between HFD-HFD and 
HFD-BAY+HFD fed mice (Figure 31a). Two hours after glucose injection, 
HFD-BAY+HFD mice had a reduced glucose level by 26.9 % compared to 
HFD-HFD mice (Figure 31a).  
The basal glucose level of HFD-CD or HFD-BAY+CD mice was not 
significantly different (Figure 31b). Two hours after glucose injection the 
glucose level of mice fed HFD-BAY+CD was reduced by 21 % compared to 
mice fed a CD (HFD-CD) (Figure 31b). These results reveal that the sGC 
stimulator improves glucose clearance after already established obesity 
and triggers a higher glucose clearance when mice were fed a 
HFD+BAY41. 
Figure 31: BAY 41-8543 improves glucose clearance after already established obesity. 
(a;b) Glucose tolerance test after established obesity. Therefore, mice were fed a HFD for 12 weeks 
and then diet was changed, to (a) HFD (HFD-HFD) or HFD plus BAY 41-8543 (HFD-BAY+HFD) for 
additional six weeks, (b) or CD (HFD-CD) and CD plus BAY 41-8543 (HFD-BAY+CD) also for six 
additional weeks, n=8 mice per group. All data are represented as mean ± SEM and statistical testing 
was performed using Student t-test, *p<0.05, ***p<0.005. 
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 The sGC stimulator BAY 41-8543 decreases adipose tissue weight 
and plasma level of insulin, leptin and adiponectin 
To unravel how the treatment of obese mice with the sGC stimulator 
improves their health in comparison to HFD fed mice, tissue weights were 
measured and the plasma level of insulin, leptin and adiponectin were 
analyzed. The WATi of HFD-BAY+HFD mice was 27 % reduced compared 
to HFD-HFD mice (Figure 32a) whereas WATi weight of HFD-BAY+CD mice 
was decreased by 24 % compared to HFD-CD mice (Figure 32a). The 
weight of WATg from HFD-BAY+HFD mice was 13 % reduced compared to 
HFD-HFD mice (Figure 32a). Surprisingly, HFD-BAY+CD mice possessed a 
decreased WATg weight by 39 % compared to HFD-CD mice (Figure 32a). 
The weight of BAT and muscle was not significantly altered in all four 
groups (Figure 32a).  
The plasma level of insulin showed a significant (56.3 %) decrease after 
changing the diet from HFD to HFD+BAY 41-8543 (HFD-BAY+HFD) 
compared to mice on HFD-HFD (Figure 32b). Interestingly, diet change 
from HFD to CD (HFD-CD) decreased the insulin plasma level to the same 
extent as a change from HFD to BAY+HFD did (Figure 32b). Addition of 
BAY41 to CD did not further decrease insulin plasma level compared to 
HFD-CD mice (Figure 32b).  
Leptin plasma levels were not significantly decreased in HFD-BAY+HFD 
mice compared to HFD-HFD mice (Figure 32b). Interestingly, HFD-BAY+CD 
mice possessed a significant decrease in leptin plasma level by 46.7 % 
compared to HFD-CD mice (Figure 32b). The levels of adiponectin were 
not significantly different between all four groups (Figure 32b). Together 
these results demonstrate that the sGC stimulator decreased the weight of 
WATi and WATg as well as the plasma levels of insulin and leptin after 
already established obesity.  
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Figure 32: BAY 41-8543 decreases adipose tissue weight and improves insulin and leptin 
secretion after already established obesity. 
(a;b) Tissue weights and plasma level after established obesity. Therefore, mice were fed a HFD for 12 
weeks and then diet was changed, to HFD (HFD-HFD) or HFD plus BAY 41-8543 (HFD-BAY+HFD) for 
additional 6 weeks, or CD (HFD-CD) and CD plus BAY 41-8543 (HFD-BAY+CD) also for six additional 
weeks, n=8 mice per group. (a) Tissue weights after 18 weeks of treatment of WATi, WATg, BAT and 
muscle. (b) Plasma level of insulin, leptin and adiponectin after 18 weeks of treatment. All data are 
represented as mean ± SEM and statistical testing was performed using Student t-test, *p<0.05, 
***p<0.005. 
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 Effects of sGC stimulator BAY 41-8543 on mice fed a CD 
 sGC stimulator BAY 41-8543 does not influence body weight nor 
body composition 
After identifying that the stimulation of sGC influenced the body weight in 
two different approaches, one question remained unsolved: What are the 
effects of sGC stimulator on weight gain in mice just fed CD for 12 weeks? 
Hence, their body weight was measured every week and additionally, in 
the last week, body composition was determined. The body weight was not 
significantly changed after treatment with BAY 41-8543 over the period of 
12 weeks. At the end of the study the body weight was not significantly 
changed in both groups (Figure 33a). Body composition showed no 
significant alteration in fat, lean mass and water content (Figure 33b).  
After sacrificing the mice, tissue weights were measured. The sGC 
stimulator did not affect the WATi weight compared to mice fed a CD only 
(Figure 33c). Interestingly, treatment with BAY 41-8543 significantly 
decreased the tissue weight of WATg by 20 % compared to mice fed the 
CD (Figure 33c). BAT weight and muscle weight was not affected by the 
stimulation of sGC (Figure 33c). Taken together, the sGC stimulator does 
not affect body weight nor body composition but reduces WATg weight. 
 
Figure 33: Effects of sGC stimulator BAY 41-8543 on body weight and composition in mice 
fed a CD. 
(a;b) Effects of control diet (CD) with or without BAY 41-8543 (CD+BAY) on body weight (a) and body 
composition (b). (c) Tissue weights of inguinal WAT (WATi) and gonadal WAT (WATg), interscapular 
brown adipose tissue with WAT (BAT) and muscle after treatment with or without BAY 41-8543. All 
data are represented as mean ± SEM and statistical testing was performed using Student t-test, 
*p<0.05. 
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 The sGC stimulator BAY 41-8543 improves glucose clearance, but 
does not affect NE-induced thermogenesis 
Treatment of non-obese mice with the sGC stimulator did not show as 
strong effects as seen in obese mice or mice fed a HFD. The only effect 
discovered so far was a decreased WATg weight. Hence, GTT and NE-
induced thermogenesis were analyzed in addition.  
The treatment with the sGC stimulator enhanced the glucose clearance 
over time compared to mice on a CD. Interestingly, the basal glucose level 
was already 12 % reduced in mice fed the sGC stimulator compared to 
mice only fed a CD (Figure 34a). The AUC was significantly reduced upon 
treatment with the sGC stimulator compared to mice fed only a CD (Figure 
34b).  
To investigate BAT activity, NE-induced thermogenesis was measured. 
Remarkably, the RMR was significantly increased in mice fed a CD 
supplemented with the sGC stimulator compared to mice fed a CD (Figure 
34c). After NE injection, mice fed a CD+BAY consumed more O2 than mice 
only fed a CD (Figure 34c). The AUC revealed that mice fed a CD+BAY 
consumed 12 % more O2 than mice fed only a CD (Figure 34d). Hence, 
these results strengthen that sGC stimulation not only acts on obese mice, 
it also improves glucose clearance and BAT activity in mice fed a CD.  
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Figure 34: Enhanced glucose clearance after BAY 41-8543 treatment in CD mice. 
(a;b) Effects of control diet (CD) with or without BAY 41-8543 on glucose clearance (a). (b) Calculation 
of the area under the curve (AUC). (c) Norepinephrine-induced (NE) thermogenesis in BAY 41-8543 
treated mice. Mice were 12 weeks fed a control diet (CD) with or without BAY 41-8543 (CD+BAY). The 
resting metabolic rate was analyzed at thermoneutrality (30°C). NE (subcutaneous injection 1mg/kg 
body weight) was used to induce maximal thermogenesis (b) Area under the curve (AUC) of mean 
oxygen consumption after NE injection; n=7 mice per group. All data are represented as mean ± SEM 
and statistical testing was performed using Student t-test, ** p< 0.01. 
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4 Discussion 
 sGC is crucial for BA differentiation and thermogenesis  
Genetic ablation of the β1 subunit of sGC in mice leads to severe phenotypes 
like, dysmotility of the gastrointestinal tract, dysfunctional smooth muscle 
relaxation, high blood pressure and postnatal death (Friebe et al., 2007). 
The β1 subunit of sGC contains a heme–binding domain, making it 
indispensable for proper functioning of sGC upon activation by NO and sGC 
stimulator (Hoffmann et al., 2009; Stasch et al., 2002b). Current 
understanding of the metabolic consequences resulting from sGC ablation is 
rudimentary. Therefore, this thesis aims to add important knowledge about 
the role of sGC in metabolism, especially in BAT and WATi, using in vitro 
and in vivo models. 
The cGMP pathway is a crucial regulator of BAT thermogenesis (Haas et al., 
2009; Pfeifer and Hoffmann, 2015). The second messenger cGMP is 
generated by two different enzymes, sGCs and pGCs (Friebe and Koesling, 
2009b; Garbers et al., 2006). PKGI, the major downstream target of cGMP, 
is essential for differentiation of BAs in vitro and in vivo, as well as for 
browning of WATi (Haas et al., 2009; Mitschke et al., 2013). Mice lacking 
the β1 subunit of sGC have a reduced BAT mass and exhibit a decreased 
UCP1 expression, resulting in diminished BAT-derived thermogenesis. To 
unravel the underlying molecular mechanisms, further analyses were 
performed using BAs in vitro. Basal cGMP concentration in mature BAs is 
reduced in sGCβ1-/- cells, compared to untreated WT cells. Stimulation with 
NO increases intracellular cGMP only in WT cells but not in sGCβ1-/- cells, 
indicating that sGCβ1 is required for NO-dependent cGMP production in BAs.  
Lipid uptake in adipocytes, their subsequent esterification and storage (as 
TGs within the lipid droplets) is important for expansion of adipose tissue 
and maintenance of metabolic homeostasis (Rutkowski et al., 2015). TG 
content of sGCβ1-/- BAs is significantly reduced in comparison to untreated 
WT BAs. Addition of 200 µM of a cGMP analog increases BAs differentiation, 
marked by enhanced UCP1, PGC1a and aP2 expression and an increased TG 
content (Haas et al., 2009).  
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Chronic cGMP treatment of sGCβ1-/- BAs throughout differentiation protocol 
restores lipid content in these cells, demonstrating that the signaling 
pathway downstream of cGMP remains intact in sGCβ1-/- BAs. Importantly, 
NO-dependent cGMP production is dependent on sGCβ1.  
The impact of sGC on the adipogenic program was investigated by analyzing 
expression levels of PPARγ and aP2. Deletion of sGCβ1 leads to decreased 
expression of PPARγ and aP2 in vitro. Earlier studies have shown that PPARγ 
is a master regulator of adipogenesis, regulating the expression of genes 
such as aP2 and C/EBPα (Carmona et al., 2005; Nedergaard et al., 2005). It 
has been previously shown that also the loss of PKGI leads to reduced 
PPARγ and aP2 expression in BAs (Haas et al., 2009). The mitochondrial 
thermogenic program is a hallmark of BAs and is highly regulated by PGC-
1a  (Cannon and Nedergaard, 1996). Furthermore, PGC-1a  is a major 
regulator of mitochondrial biogenesis and energy homeostasis (Fernandez-
Marcos and Auwerx, 2011). sGCβ1-/- cells exhibit a decreased expression of 
UCP1 and PGC-1a. Moreover, similar observations are made upon genetic 
ablation of PKGI in BAs (Haas et al., 2009). In this study, mtDNA 
expression analysis revealed that sGCβ1-/- cells express less PGC-1a  and 
mtDNA (Nd1, Cytb, Co1). These results are in line with the previously 
published data where PGC-1a  activates nuclear and non-nuclear receptors, 
like mitochondrial transcription factor (mtTFA) and nuclear respiratory 
factors (NRF) 1 and 2, which are important for replication and transcription 
of mitochondrial DNA (Bogacka et al., 2005).  
In comparison to WT cells, basal lipolytic activity is decreased in sGCβ1-/-
cells. After stimulation with NE, an increased lipolytic activity is observed in 
sGCβ1-/- cells compared to untreated sGCβ1-/- cells. However, lipolysis in NE-
stimulated sGCβ1-/- cells increases by a lesser extent than in NE-treated WT 
cells. These results indicate that the deletion of sGC decreases the NE-
induced lipolytic activity. NE release (from sympathetic nerves in BAT) is 
dramatically increased upon cold exposure (Young et al., 1982). 
Intracellular levels of eNOS, NO and cGMP are modulated by NE.  
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This leads to upregulated eNOS expression, enhanced NO production, 
increased intracellular cGMP level and a corresponding upregulation of UCP1 
expression (Giordano et al., 2002). Nevertheless, this is not working in 
sGCβ1-/- cells because NO cannot activate sGC in this cells. NE induces also 
PGC-1a  expression, which binds to the UCP1 promotor and increases UCP1 
expression (Lowell and Spiegelman, 2000).  NE, by binding with b-ARs, 
elevates intracellular cAMP production, which results in activation of the PKA 
pathway. This leads to an increased lipolysis of FFA from TG. FFA are then 
oxidized by mitochondria to produce heat (Cannon and Nedergaard, 2004). 
VASP-/- BAs have an increased b-ARs expression, which leads to enhanced 
lipolytic activity (Jennissen et al., 2012). Moreover, VASP-/- cells show 
increased TG accumulation and adipogenic marker expression, thus 
highlighting the importance of VASP and cGMP signaling in BAs (Jennissen 
et al., 2012). Deletion of VASP in BAs leads to increased Rac-1 activity, 
which enhances sGC expression and consequently, leads to higher cGMP 
production (Jennissen et al., 2012). Diminished NE-induced lipolytic activity 
in sGCβ1-/- BAs suggests that the absence of sGC leads to decreased b-AR 
expression, which in turn reduces lipolytic activity in adipocytes.  
To summarize, sGCβ1 is crucial for normal BAT differentiation. Deletion of 
sGCβ1 inhibits adipogenic (TG content and PPARγ and aP2 expression) and 
thermogenic programs (diminished mitochondrial biogenesis and lipolytic 
activity) in vitro. 
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 Stimulation of sGC with BAY 41-5843 influences adipogenesis of brown 
adipocytes 
As demonstrated, sGC is crucial for adipogenic differentiation and 
thermogenic function of BAs. Consequently, the effects of pharmacological 
stimulation of sGC with BAY 41-8543 was assessed in BAs. The sGC 
stimulator BAY 41-8543 is known to stimulate sGC in a NO- and heme 
dependent manner, thus resulting in enhanced cGMP production. To date, 
effects of the sGC stimulator have only been investigated in smooth muscle 
cells, colon and aorta (Adderley et al., 2012; Monica et al., 2012; Soares et 
al., 2013; Thorsen et al., 2010). Accordingly, there are no functional data 
available describing the effects of sGC stimulation with BAY 41-8543 in 
adipocytes. 
Application of BAY 41-8543 throughout differentiation positively influences 
the adipogenic differentiation as well as thermogenic program (increased 
UCP1 expression). In agreement, Nisoli et al. have shown an enhanced 
PPARg expression in BAs upon treatment with an NO-Donor (Nisoli et al., 
1998). Furthermore, a treatment with DETA/NO or BAY 41-8543 also 
increases the expression of the thermogenic marker UCP1, which is 
responsible for thermogenesis. In line with previously published work in 
vitro results presented here demonstrate increased UCP1 expression upon 
activation of the cGMP/PKGI pathway (Haas et al., 2009). Thus, 
pharmacological stimulation of sGC results in opposite effects as shown in 
sGCβ1-/- cells.  
BAs treated with BAY 41-8543 exhibit an elevated TG content and lipolytic 
activity. Additionally, it has been reported that higher fat content in BAs 
provides an increased pool of lipids for lipolysis. TGs are broken down into 
diacylglycerols, then into monoglyceride and finally into fatty acids and 
glycerol (Lafontan, 2008). Thus, BAs treated with BAY 41-8543 have an 
enhanced lipolytic activity, as the rate-limiting step in adipose tissue 
lipolysis is the hydrolysis of TG by lipases. 
Taken together, stimulation of the sGC/cGMP/PKGI pathway promotes BAs 
differentiation in vitro.   
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 The effect of pharmacological stimulation of sGC on metabolism 
 Stimulation of sGC increases BAT activity and browning of WAT in 
vivo 
After showing that stimulation of sGC increases BAs differentiation in vitro, 
the effects of BAY 41-8543 on the whole body metabolisms was 
investigated. A 12-week treatment with the sGC stimulator increases UCP1 
expression in BAT. Consequently, enhanced BAT activity and higher oxygen 
consumption after acute NE stimulation is observed in mice co-fed a HFD 
and sGC stimulator compared to CD fed mice. In accordance, Gnad et al. 
have demonstrated that an acute NE treatment significantly increases O2 
consumption in mice fed a HFD (Gnad et al., 2014). Importantly, the sGC 
stimulator increases energy expenditure (EE) and lipid uptake into BAT 
under basal conditions. It has been shown that more than 50 % of nutrients 
lipids can be metabolized by active BAT, which leads to increased EE 
(Bartelt et al., 2011; Gnad et al., 2014; Moro et al., 2007; Ouellet et al., 
2012). Likewise, muscle, WAT and liver also incorporate and subsequently 
utilize more lipids after treatment with the sGC stimulator. Congruently, the 
expression of lipid processing genes, such as Adbr3, Nrf1, Pgc-1a, Lpl and 
Cd36, is increased in BAT from mice treated a HFD with the sGC stimulator 
in comparison to CD mice. Nrf1 and Pgc-1a  are important for the 
transcription of mitochondrial DNA (Bogacka et al., 2005; Fernandez-Marcos 
and Auwerx, 2011). In agreement with these studies, expression of 
mitochondrial markers, such as Co1 and Cytb is significantly increased in 
BAT from mice treated a HFD with sGC stimulator compared to CD. These 
results indicate that sGC stimulator mediated upregulation of mitochondrial 
markers may lead to increased energy supply in BAT.  
Whitening of BAT is characterized by diminished b-adrenergic signaling, 
accumulation of large lipid droplets, mitochondrial dysfunction as well as 
loss of VEGF expression (Shimizu et al., 2014). In BAT sections of mice only 
fed a HFD whitening of BAT and adipocyte hypertrophy could be illustrated. 
This is in line with Gao et al. that showed that whitening of BAT is 
associated with adipocyte hypertrophy, increased expression of 
inflammation markers, excessive fat accumulation and ectopic lipid 
deposition (Gao et al., 2015). 
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In comparison to mice fed a HFD, mice co-fed a HFD and the sGC stimulator 
exhibit a reduced whitening in BAT, resulting in smaller lipid droplets, 
enhanced mitochondrial biogenesis, increased VEGF expression and b3-AR 
expression.  
In mice fed with the sGC stimulator, the browning capacity of WATi is 
enhanced. Whereas, the white adipocyte diameter is decreased. This study 
adds the sGC stimulator BAY 41-8543 to the list of compounds capable to 
increase browning capacity of WATi. Increased cGMP levels in BAs and WAs 
result in elevated UCP1 expression (Bordicchia et al., 2012; Haas et al., 
2009; Nisoli et al., 2003). Likewise, inhibition of PDEs increases intracellular 
cGMP level in WAs, thus leading to browning in WATi (Mitschke et al., 2013; 
Moro et al., 2007). Browning of WAs is induced by stimulation of the cGMP 
cascade (Mitschke et al., 2013; Roberts et al., 2015). Furthermore, 
browning of WAs can be stimulated by several other agents like 
sympathomimetics, prostaglandins, PPARg activators, FGF21, NP and irisin 
(Bordicchia et al., 2012; Bostrom et al., 2012; Fisher et al., 2012; Petrovic 
et al., 2010; Vegiopoulos et al., 2010).  
Mice treated with the sGC stimulator and HFD for 12 weeks have smaller 
white adipocytes diameter compared to mice fed only a HFD. Furthermore, 
mtDNA content in WATi of sGC stimulator treated mice is significantly 
increased compared to CD fed mice. Intriguingly, plasma insulin levels are 
similar in mice treated with the sGC stimulator and to CD fed mice, but 
lower compared to mice fed a HFD. It has previously been described that 
young adipocytes are relatively small, insulin sensitive and are 
characterized by increased adiponectin expression. During aging, cells 
increase in size and lose function and adiponectin synthesis (Yu and Zhu, 
2004). Reduced adipocyte size is also an indicator for healthy fat expansion 
(Sun et al., 2011). Furthermore, mitochondrial biogenesis during adipocytes 
differentiation is increased but the amount of mitochondria is reduced in 
obese db/db mice (Choo et al., 2006). Mitochondrial biogenesis is essential 
for adipocyte differentiation while a reduction in mitochondrial mass causes 
adipocyte hypertrophy (Wilson-Fritch et al., 2003; Yu and Zhu, 2004). 
These findings highlight that the sGC stimulator leads to decreased 
expansion of WAT, higher mtDNA content and to a higher insulin sensitivity.  
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Mice treated with the sGC stimulator have a better glucose clearance and 
reduced plasma insulin levels compared to HFD fed mice. The loss of PKGI 
leads to abrogation of cGMP pathway, increased insulin resistance, and 
subsequently to suppression of BAT function and differentiation (Haas et al., 
2009). It is known that RhoA, a small GTPase involved in insulin secretion, 
is inhibited by PKGI (Haas et al., 2009). The exact involvement of the 
NO/cGMP signaling pathway on the regulation of insulin secretion, however, 
remains elusive and there is no distinct explanation, why sGC stimulation 
leads to reduced plasma insulin level in mice (Kaneko et al., 2003; Ropero 
et al., 2010).  
Moreover, it is known that regulation of adiponectin secretion inversely 
correlates with BMI and body fat (Arita et al., 1999). Although fat mass is 
reduced in obese mice treated with BAY 41-8543, no significant changes in 
plasma adiponectin levels are observed. Different studies on adiponectin 
secretion have revealed an inhibition of hepatic glucose production, 
increased glucose uptake in muscle, enhanced oxidation of fatty acids in 
muscle and liver, accompanied by increased EE (Berg et al., 2001; Combs 
et al., 2001; Fruebis et al., 2001). Furthermore, overexpression of 
adiponectin seems to be protective against insulin resistance and has anti-
inflammatory effects (Kern et al., 2003; Maeda et al., 2002). 
The cGMP/PKGI pathway, as described earlier, is a crucial regulator of BAT 
thermogenesis and for WATi browning (Haas et al., 2009; Mitschke et al., 
2013; Pfeifer and Hoffmann, 2015). The here presented in vivo study shows 
that stimulation of sGC with BAY 41-8543 enhanced differentiation of BAT 
(comparable to in vitro experiments on BAs). Additionally, this study reveals 
that pharmacological stimulation of the sGC protects against DIO. Reduced 
weight gain is accompanied by improved overall metabolic status, indicated 
by reduced insulin signaling, improved glucose tolerance and decreased 
adipocyte diameter in WATi. 
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 Pharmacological stimulation of sGC decreases fatty liver and 
enhances muscle function 
sGC is ubiquitously expressed, thus oral sGC stimulator administration 
affects not only adipose tissue or adipocytes, but also other cells and organs 
(Potter, 2011). Skeletal muscle and liver from mice treated with sGC 
stimulator seem to be protected against excess fat accumulation, even 
though the lipid uptake is increased in both tissues. Importantly, mice 
treated with the sGC stimulator are insulin sensitive. Insulin resistance is 
strongly associated with skeletal and hepatic lipid content (Lee et al., 
2014a; Morino et al., 2012). It develops in skeletal muscle and liver in case 
of an imbalance between uptake and utilization of intracellular lipids, such 
as diacylglycerol (Lee et al., 2014a). This lipid accumulation is primarily 
achieved by caloric intake exceeding the capacity of myocytes and 
hepatocytes, leading to obesity or metabolic syndrome (Birkenfeld and 
Shulman, 2014; Samuel and Shulman, 2012). These cell types metabolize 
and export fatty acids while refining or uncoupling mitochondrial respiration 
and enhancing lipid oxidation, which leads to an improved insulin sensitivity 
(Birkenfeld et al., 2011; Kumashiro et al., 2013; Lee et al., 2010; 
Neuschafer-Rube et al., 2014; Perry et al., 2013; Thielecke et al., 2010).  
Nutrient excess in cultured hepatocytes and hepatic tissues promotes 
inflammatory signaling and insulin resistance. The study of Tateya et al. 
shows that during HFD liver NO levels are reduced. This triggers hepatic 
inflammation and impairment of insulin signaling (Tateya et al., 2011). 
Chronic treatment with PDE inhibitor Sildenafil, which inhibits cGMP 
degradation by PDE5, is able to prevent the HFD-dependent hepatic 
inflammation and insulin resistance (Tateya et al., 2011). Another study 
reports that deletion of PKGI reduces liver inflammation, fasting 
hyperglycemia and insulin tolerance (Lutz et al., 2011). Mice lacking eNOS 
are more resistant to insulin (Duplain et al., 2001; Shankar et al., 2000). 
Additionally, An et al. have shown that cGMP has a direct impact on liver 
homeostasis in terms of inflammatory status and insulin signaling. They 
have demonstrated that cGMP infusion (intraportal) in fasted, glucose-
infused dogs decreases the glucose uptake in the liver.  
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Moreover, they have observed a decrease of NO after food consumption in 
dogs and they speculated that low cGMP levels might facilitate hepatic 
glucose uptake (An et al., 2012; Bandsma et al., 2001). In all three studies 
performed within this thesis - mice treated with BAY41-8543 and a HFD, a 
CD or after established obesity - BAY 41-8543 always improves the glucose 
clearance from blood circulation. This argues that administration of the sGC 
stimulator protects against liver inflammation and insulin intolerance.  
Genes involved in gluconeogenesis (Gcp6), oxidative stress detoxification 
(CAT) and energy dissipation (Ucp2) in the liver have also been analyzed in 
this thesis. An increase in CAT mRNA expression in mice fed a HFD or a HFD 
with sGC stimulator can be explained by the fact that peroxisomal b-
oxidation of fatty acids generates H202, that needs to be efficiently removed 
by catalase. A higher H202 content has been linked to in increased 
expression of CAT (Carmiel-Haggai et al., 2005). Moreover, Ucp2 mRNA 
expression in liver of mice treated with a HFD or HFD plus sGC stimulator is 
unchanged compared to CD fed mice. Ucp2 is expressed in liver 
mitochondria and suppresses H202 production. Chavin et al. demonstrate 
that increased Ucp2 expression in fatty liver of ob/ob mice (Chavin et al., 
1999). Gcp6 is a key enzyme in hepatic glucose metabolism. Alteration in 
Gcp6 activity leads to an impairment of lipid metabolism, as observed in 
patients with glycogen storage disease and diabetic states (Bandsma et al., 
2001). Acute inhibition of the Gcp6 system stimulates hepatic de novo 
lipogenesis in rats and decreases circulating levels of insulin, which is a 
stimulator of lipogenesis (Bandsma et al., 2001). In line with these results, 
mice treated with the sGC stimulator have decreased Gcp6 levels and 
reduced plasma insulin levels, in comparison to mice fed a HFD. Therefore, 
it can be speculated that BAY 41-8543 inhibits the Gcp6 system and hence 
prevents the development of a fatty liver in mice.  
Studies on mice overexpressing PKGI and fed a HFD have revealed a higher 
EE, lower fat mass and higher expression of mitochondrial biogenesis 
marker in skeletal muscle compared to WT mice (Miyashita et al., 2009). 
Similar results are obtained in WT mice fed the sGC stimulator and a HFD. 
Mice treated with the sGC stimulator have a higher EE, lower fat mass as 
well as higher mitochondrial biogenesis in skeletal muscle.  
4. Discussion 
   
 
 
93 
Additionally, qRT-PCR results on muscle from mice treated with BAY 41-
8543 reveal significantly increased expression of the mitochondrial marker 
UCP3 and PGC-1α. In vitro experiments have pointed out that the NP/cGMP 
pathway stimulates mitochondrial biogenesis (Mitsuishi et al., 2008). In 
human myocytes, the NP/cGMP signaling pathway activates UCP3 and 
ATP/ADP translocase 1, which increases basal proton leak and energy 
uncoupling (Larsen et al., 2011). Furthermore, studies of Deshmukh et al. 
have shown a direct effect of cGMP on glucose uptake into muscle. 
Activation of the cGMP signaling in ex vivo human muscle strip increases 
cGMP levels and insulin–independent glucose transport and glycogen 
synthesis (Deshmukh et al., 2010). Similarly, mice treated with the sGC 
stimulator have increased mRNA expression of marker involved in glucose 
and lipid uptake, as well as fatty acid metabolism.  
Skeletal muscles of mammalians contain myofibers that differ in 
mitochondrial content and contraction as well as metabolic properties. The 
most informative methods to describe muscle fiber types are based on 
specific myosin profiles, especially the myosin heavy chain (MHC). The 
comparison between slow (type I, slow twitch, MHCI) muscles and fast 
(type II, fast twitch, MHCIIa, IIb, IIx) muscles reveal that slow muscles are 
high in capillary density and mitochondrial volume, contain greater 
proportions of aerobic enzymes and are generally fatigue resistant (Koerker 
et al., 1990). It is widely accepted that healthy skeletal muscle can easily 
switch between glucose and fat oxidation and use fat as a source for 
energy. Interestingly, slow muscles have a greater sensitivity to insulin 
when compared to fast muscle phenotypes. Recent studies reported that 
MHC expression can be influenced by physical activity (Klitgaard et al., 
1990; Minetto et al., 2013; Mosole et al., 2014), aging (Klitgaard et al., 
1990; Mosole et al., 2014; Short et al., 2005; Vandervoort, 2002), and diet 
or obesity (Kriketos et al., 1996; Krotkiewski and Bjorntorp, 1986; Lillioja et 
al., 1987; Matsakas and Patel, 2009; Tanner et al., 2002). In a HFD study, 
it has been shown that fibers expressing MHC type I in rodent and human 
muscles are reduced, suggesting a decrease in overall oxidative capacity, 
insulin sensitivity and glucose tolerance (Kriketos et al., 1996; Lillioja et al., 
1987).  
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In the 12-week study performed in this thesis, HFD increases albeit not 
significantly- the expression of MHCI, but does not affect expression of 
marker proteins for the fast twitch muscles. Interestingly, treatment with 
the sGC stimulator and HFD significantly increases the expression of MHCI, 
MHCIIa and MHCIIb. These results suggest that stimulation of sGC affects 
the muscle fiber type towards slow muscle, which are more sensitive to 
insulin. Additionally, the glucose tolerance test also reveals a greater 
glucose clearance in mice treated with the sGC stimulator, which argues for 
a higher insulin sensitivity. Another study on mice fed a HFD has 
demonstrated that HFD changed the muscle transcriptome and that the 
level of slow working muscle is increased (MHCI). This effect was explained 
by an increased expression of PGC-1α as an important regulator for muscle 
fiber type determination (de Lange et al., 2006; de Wilde et al., 2008). As 
described before, mice co-fed a HFD and the sGC stimulator also express 
more PGC-1α in muscles. Of note, the muscle study has its own limitations. 
Entire calf muscles were analyzed for MHC expression. The muscle, 
however, also includes soleus that expresses classical marker of type I 
fibers, and gastrocnemius that expresses low levels of MHCI and higher 
levels of MHC type II (Lin et al., 2002). Therefore, it cannot be ruled out 
that during RNA isolation different rates of soleus or gastrocnemius muscle 
were used, that may result in misleading expression levels, leading to minor 
effects.  
To sum up, mice treated with the sGC stimulator exhibit increased lipid 
uptake, but are characterized by a reduced lipid storage. Interestingly, the 
stimulation with the sGC stimulator leads to a muscle fiber type switch and 
an increased mitochondrial biogenesis in muscle.  
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 sGC stimulation as a potential therapeutic approach against obesity  
Since obesity has reached pandemic proportions, an urgent need for reliable 
therapies is necessary. Currently, only two anti-obesity drugs are available 
in Europe; Orlistat and Liraglutide. Orlistat is a lipase blocker that reduces 
hydrolysation and absorption of fat by inhibition of pancreatic lipases. 
(Hogan et al., 1987). It is associated with gastrointestinal side effects such 
as cramps, flatulence and fatty stools (Lucas and Kaplan-Machlis, 2001). 
Since 2015, the GLP-1 analog Liraglutide is available (Pi-Sunyer et al., 
2015a; Pi-Sunyer et al., 2015b). This drug imitates glucagon-like 1 peptide 
(GLP-1), an incretin hormone released by cells located in the ileum and 
colon (Flock et al., 2007; Hadjiyanni and Drucker, 2007; Yamada et al., 
2008). This drug is a promising candidate to fight obesity due to numerous 
physiological effects: it increases insulin secretion, decreases glucagon 
secretion, slows gastric emptying and decreases appetite (Turton et al., 
1996). Nonetheless, because of the low body weight reduction and the 
intense side effects, both drugs have limitations as anti-obesity drugs. 
Therefore, new potential drug targets need to be identified. 
One such candidate to act as potential target for a new anti-obesity drugs is 
BAT. It is described that 60-100 g of activated BAT could burn 3-4 kg of fat 
per year (Virtanen et al., 2009). Beiroa et al. have investigated the effects 
of GLP-1 agonist on BAT thermogenesis and browning (Beiroa et al., 2014). 
A direct injection of Liraglutide in mice stimulates BAT thermogenesis and 
adipocytes browning independent of nutrient intake. In a human study on 
obese type 2 diabetic patients, treatment with Liraglutide for one year led to 
an increased in EE (Beiroa et al., 2014). In another study, Liraglutide 
affected the proliferation and differentiation of human adipose stem cells 
from subcutaneous adipose tissue. Liraglutide significantly reduced glucose 
uptake as well as intracellular lipid accumulation (Beiroa et al., 2014). Both 
studies clearly show the promising effects of these drugs on EE and adipose 
tissue differentiation, but still these drug show low body weight reduction 
and the intense side effects in long-term studies (Pi-Sunyer et al., 2015a; 
Pi-Sunyer et al., 2015b). 
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The sGC/cGMP pathway could represent another important target for anti-
obesity drugs. It is an important signaling cascade that can be regulated at 
several levels and thus, the involvement of sGC in metabolism was 
investigated in detail.  
This cascade starts with the endogenous ligand of sGC, NO. Organic nitrates 
for example have been used for more than 100 years to treat angina 
pectoris. NO treatment leads to an increased differentiation of BAs (Nisoli et 
al., 1998). NO is volatile and acts in the vascular system. However, a BAT 
specific treatment with a NO-analog against obesity is not possible due to 
nitrate tolerance after a long–term treatment (Munzel et al., 2014).  
Another, well studied, enhancers of cGMP production are NPs. NPs activate 
NPR-A and NPR-B and have been shown to counteract in DIO as well as 
increase the expression of thermogenic markers in inducible BAs. 
Furthermore, they are capable of increasing EE in mice with concomitant 
browning of WAT (Bordicchia et al., 2012; Miyashita et al., 2009). A new 
designer NP, CD-NP, also activated cGMP production and promoted 
adipogenesis, as well as increased thermogenic markers in BAs (Glode et 
al., 2017). Mice treated 10 days with CD-NP showed increased browning 
capacity, but in this study divergent effects were observed depending on 
the duration of treatment (Glode et al., 2017). Recently, it has been shown 
that decreased expression of the NPRs in adipose tissue is associated with 
obesity, glucose intolerance and insulin resistance in humans (Kovacova et 
al., 2016). BNP, as one candidate of NPs, has been used as a drug to treat 
acute decompensated heart failure. Use of BNP might not be suitable for all 
obese patients as its safety has been questioned (Sackner-Bernstein et al., 
2005a; Sackner-Bernstein et al., 2005b). An effect of administered NPs on 
body weight in clinical trials has not been published so far. Currently, there 
are two ongoing studies investigating the effects of NPs on metabolism.  
Targeting cGMP signaling can be achieved not only by enhancing cGMP 
production, but also through inhibiting endogenous cGMP breakdown. One 
such therapeutically relevant target is PDE5. Sildenafil, a clinically approved 
PDE5 inhibitor, has been shown to increase intracellular cGMP levels (Turko 
et al., 1999). 
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Members of PDE5 inhibitors have been used mainly for erectile dysfunction 
for several years (Gareri et al., 2014; Salvi et al., 2004). Short-term 
treatment with Sildenafil results in browning, while chronic treatment 
results in less weight gain in mice on a HFD (Ayala et al., 2007; Mitschke et 
al., 2013). Sildenafil has adverse effects like headache, flushing, 
indigestion, blurred vision and most notably, it interacts with agents that 
lower blood pressure such as nitrates, sGC stimulator or alpha blockers. 
Furthermore, an increased risk of melanoma has also been reported 
(Kloner, 2004; Kloner et al., 2004; Schwartz and Kloner, 2010).  
Therefore, alternative strategies to increase cGMP signaling in adipocytes 
are necessary for develop a viable anti-obesity therapy without or with less 
side effects. To increase intracellular cGMP levels via the sGC pathway, a 
new drug class was used: sGC stimulator. These compounds stimulate sGC 
in a heme-dependent manner and show a strong synergism with NO 
(Stasch and Hobbs, 2009). Soluble GC stimulation can be achieved even 
when the endogenous NO/cGMP signaling is impaired, due to reduced 
bioavailability of NO. Treatment of obese patients with a sGC stimulator 
could synergistically work with NO and consequently boost lipolysis in 
subcutaneous adipose tissue and therby decrease weight gain. A study on 
obese patients showed that gene expression and protein levels of eNOS are 
increased, but HSL protein levels are decreased compared to lean patient 
(Elizalde et al., 2000). This suggests that increased NO production (by 
eNOS) and decreased HSL levels may impede lipolysis in subcutaneous 
adipose tissue during obesity and might help in weight reduction  (Elizalde 
et al., 2000). 
The compound used in this study is chemically related to Riociguat, which is 
used for pulmonary hypertension and shows a favorable safety profile (Frey 
et al., 2011; Ghofrani et al., 2013b). Side effects, such as hypotension, 
headache, diarrhea and dizziness have been reported in patients treated 
with 2.5 mg of Riociguat, thrice a day (Ghofrani et al., 2013b; Ghofrani et 
al., 2016). Since patients with obesity were excluded from these studies, 
the effects of Riociguat in obese human subjects cannot be estimated. 
Notably, all the patients in the Riociguat clinical trial had a normal body 
weight (Ghofrani et al., 2013a; Ghofrani et al., 2013b).  
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In addition, patients suffering from pulmonary hypertension rather tend to 
have a lower body weight because of their severe disease. A significant 
change in body weight was not observed in the clinical trials (Ghofrani et 
al., 2013a; Ghofrani et al., 2013b; Ghofrani et al., 2016; Ghofrani et al., 
2013c; Ghofrani et al., 2015).  
Nevertheless, the sGC stimulator is a promising candidate as anti-obesity 
drug as it increases BAs activity and induces browning in WATi after sGC 
stimulation in mice (Figure 35). Moreover, sGC stimulation counteracts DIO-
induced pathologies even in already established murine obesity, by 
increasing energy expenditure. Stimulation of sGC also results in increased 
lipid uptake and utilization, mainly by BAT. Overall, sGC stimulation leads to 
reduced body weight and improved metabolic phenotype in mice with DIO. 
Additionally, comorbidities of overweight like fatty liver and insulin 
resistance are curtailed after sGC stimulation. 
 
 
Figure 35: Pharmagological sGC stimulation counteracts against obesity. 
Graphic overview about the effect of the pharmacological stimulation of sGC on mice fed a HFD.  
 
In summation, sGC stimulation represents an innovative pharmacological 
principle, with sGC stimulators as potential candidates for developing viable 
anti-obesity therapies. 
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5 Summary 
Obesity is a worldwide health problem characterized by a chronic positive 
energy balance. The excess energy is stored primarily as lipids (TGs) in 
white adipose tissue (WAT). In contrast, brown adipose tissue (BAT) utilizes 
energy to produce heat in response to cold exposure. BAT is a promising 
target for developing anti-obesity therapies. This thesis focusses on the role 
of soluble guanylate cyclase (sGC) in metabolism and identifies BAT-
centered therapies.  
Analysis of sGCβ1 knockout mice revealed reduced BAT mass and less UCP1 
expression in comparison to WT mice. Furthermore, differentiation and 
function of brown adipocytes was impaired in mice lacking the β1 subunit of 
sGC. Congruently, chronic stimulation of sGC with 3 µM BAY 41-8543 during 
differentiation of brown adipocytes (BAs) resulted in improved adipogenic 
(PPARg and aP2) and thermogenic marker (PGC-1a and UCP1) expression. 
Functionally, lipolysis, was also enhanced in BAs treated with BAY 41-8543.  
Pharmacological stimulation of sGC during a high fat diet regime protects 
against weight gain. Stimulation of sGC increases function of BAs and 
energy consumption by UCP1 mediated thermogenesis. Importantly, BAY 
41-8543 counteracts comorbidities of obesity, such as fatty liver and 
diabetes, even in already established obesity via increased energy 
expenditure. Notably, mice treated with the sGC stimulator exhibited 
reduced “whitening” of BAT and enhanced “browning” of WAT. In addition, 
sGC stimulation leads to increased expression of mitochondrial markers in 
muscle, which shows the overall effect of sGC stimulation. Stimulation of 
sGC results in increased lipid uptake and utilization by BAT, WATi, liver and 
muscle. Overall, sGC stimulation leads to reduced body weight gain, even in 
obese mice. Moreover, sGC stimulation improves metabolic phenotype in 
mice with diet-induced obesity (DIO), as well as on control diet (CD).  
Therefore, sGC stimulators represent a novel pharmacological approach for 
the treatment of obesity and its comorbidities. 
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